Author: "C, Bachert" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"C, Bachert"' showing total 1,008 results

Start Over Author "C, Bachert"

1,008 results on '"C, Bachert"'

1. The alphaherpesvirus gE/gI glycoprotein complex and proteases jointly orchestrate invasion across the host’s upper respiratory epithelial barrier

Author: E. Van Crombrugge, X. Ren, S. Glorieux, I. Zarak, W. Van den Broeck, C. Bachert, N. Zhang, T. Van Zele, D. Kim, G. A. Smith, K. Laval, and H. Nauwynck
Subjects: alphaherpesvirus, upper respiratory tract, pathogenesis, mucosa invasion, gE/gI complex, proteases, urokinase plasminogen activator, Microbiology, QR1-502
Abstract: ABSTRACT Alphaherpesviruses, including herpes simplex virus type 1 (HSV-1), pseudorabies virus (PRV), and bovine herpesvirus type 1 (BoHV-1), are significant pathogens affecting humans and animals. These viruses penetrate the upper respiratory tract mucosa, yet the mechanisms facilitating this invasion are not fully understood. This study investigates the role of the gE/gI glycoprotein complex and proteases in mucosal invasion by these viruses. Using species-specific respiratory mucosal explants, we observed that the removal of extracellular calcium disrupts epithelial junction integrity, enhancing viral infection across all viruses and suggesting a common mechanism of targeting a basolaterally located receptor. PRV exhibited significantly faster replication and deeper invasion compared to HSV-1 and BoHV-1. The gE glycoprotein was consistently polarized at the basement membrane across all viruses, indicating a critical role in the process of viral entry and subsequent spread through the epithelium. In this context, “infection” refers to the virus’s attachment to its cell-surface receptor, entry into the cell, and completion of the viral life cycle, culminating in the production of progeny virions. Notably, in gE/gI null mutants of PRV and HSV-1, while the infection was not abortive and the viral life cycle was completed, the infection was delayed, and the invasion into the deeper layers of the epithelium and underlying mucosa was significantly reduced. In BoHV-1 mutants, this effect was even more pronounced, with infection restricted to the apical cells, failing to progress to the basal cells. In addition, PRV and HSV-1 invasion involved serine protease activity, unlike BoHV-1, which correlates with its slower invasion pace. Notably, the protease facilitating PRV invasion was identified as a urokinase plasminogen activator (uPA), while the specific protease for HSV-1 remains unidentified. These findings highlight the critical roles of the gE/gI complex and proteases in alphaherpesvirus pathogenesis, offering potential targets for therapeutic intervention.IMPORTANCEHerpes simplex virus type 1 (HSV-1) infections are a worldwide issue. More than three billion people are infected with HSV-1 globally. Although most infections with HSV-1 occur subclinically, severe symptoms and complications are numerous and can be life-threatening. Complications include encephalitis and blindness. Recently, HSV-1 infections have been associated with the development of Alzheimer's Disease. To date, no effective vaccines against HSV-1 are on the market. Pseudorabies virus (PRV) and bovine herpesvirus type 1 (BoHV-1) are two alphaherpesviruses of major veterinary importance. Although efforts have been made to eradicate these viruses from livestock animals, clinical problems still occur, resulting in great economic losses for farmers. It is evident that new insights into the pathogenesis of alphaherpesviruses are needed, to develop effective treatments and novel preventive therapies.
Published: 2024
Full Text: View/download PDF

2. Association between outdoor air pollution and chronic rhinosinusitis patient reported outcomes

Author: S. Peeters, C. Wang, E. M. Bijnens, D. M. A. Bullens, W. J. Fokkens, C. Bachert, P. W. Hellings, T. S. Nawrot, and S. F. Seys
Subjects: Chronic rhinosinusitis, Outdoor air pollution, Patient reported outcome measures, Industrial medicine. Industrial hygiene, RC963-969, Public aspects of medicine, RA1-1270
Abstract: Abstract Background The aetiology of chronic rhinosinusitis (CRS) is multifactorial with a complex interplay between environmental, microbial endogenous and genetic factors. The impact of outdoor air pollution on prevalence or severity of CRS remains largely unknown. Methods Real-life geolocation data (2017–2018, Belgium) from 278 CRS patients (2576 health records) using the mySinusitisCoach mobile application were analysed to calculate the patients’ individual exposure to outdoor air pollutants (ozone (O3), black carbon (BC), nitrogen dioxide (NO2) and particulate matter with diameter
Published: 2022
Full Text: View/download PDF

3. INFERRING ROOF SEMANTICS FOR MORE ACCURATE SOLAR POTENTIAL ASSESSMENT

Author: I. Apra, C. Bachert, C. Cáceres Tocora, Ö. Tufan, O. Veselý, and E. Verbree
Subjects: Technology, Engineering (General). Civil engineering (General), TA1-2040, Applied optics. Photonics, TA1501-1820
Abstract: In guiding the energy transition efforts towards renewable energy sources, 3D city models were shown to be useful tools when assessing the annual solar energy generation potential of urban landscapes. However, the simplified roof geometry included in these 3D city models and the lack of additional semantic information about the buildings’ roof often yield less accurate solar potential evaluations than desirable. In this paper we propose three different methods to infer and store additional information into 3D city models, namely on physical obstacles present on the roof and existing solar panels. Both can be used to increase the accuracy of roof solar panel retrofit potential. These methods are developed and tested on the open datasets available in the Netherlands, specifically AHN3 lidar point-cloud and PDOK aerial photography. However, we believe they can be adapted to different environments as well, based on the available datasets and their precision locally available.
Published: 2021
Full Text: View/download PDF

4. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

Author: J. Bousquet, A. Bedbrook, W. Czarlewski, G. L. Onorato, S. Arnavielhe, D. Laune, E. Mathieu-Dupas, J. Fonseca, E. Costa, O. Lourenço, M. Morais-Almeida, A. Todo-Bom, M. Illario, E. Menditto, G. W. Canonica, L. Cecchi, R. Monti, L. Napoli, M. T. Ventura, G. De Feo, W. J. Fokkens, N. H. Chavannes, S. Reitsma, A. A. Cruz, J. da Silva, F. S. Serpa, D. Larenas-Linnemann, J. M. Fuentes Perez, Y. R. Huerta-Villalobos, D. Rivero-Yeverino, E. Rodriguez-Zagal, A. Valiulis, R. Dubakiene, R. Emuzyte, V. Kvedariene, I. Annesi-Maesano, H. Blain, P. Bonniaud, I. Bosse, Y. Dauvilliers, P. Devillier, J. F. Fontaine, J. L. Pépin, N. Pham-Thi, F. Portejoie, R. Picard, N. Roche, C. Rolland, P. Schmidt-Grendelmeier, P. Kuna, B. Samolinski, J. M. Anto, V. Cardona, J. Mullol, H. Pinnock, D. Ryan, A. Sheikh, S. Walker, S. Williams, S. Becker, L. Klimek, O. Pfaar, K. C. Bergmann, R. Mösges, T. Zuberbier, R. E. Roller-Wirnsberger, P. V. Tomazic, T. Haahtela, J. Salimäki, S. Toppila-Salmi, E. Valovirta, T. Vasankari, B. Gemicioğlu, A. Yorgancioglu, N. G. Papadopoulos, E. P. Prokopakis, I. G. Tsiligianni, S. Bosnic-Anticevich, R. O’Hehir, J. C. Ivancevich, H. Neffen, M. E. Zernotti, I. Kull, E. Melén, M. Wickman, C. Bachert, P. W. Hellings, G. Brusselle, S. Palkonen, C. Bindslev-Jensen, E. Eller, S. Waserman, L. P. Boulet, J. Bouchard, D. K. Chu, H. J. Schünemann, M. Sova, G. De Vries, M. van Eerd, I. Agache, I. J. Ansotegui, M. Bewick, T. Casale, M. Dykewick, M. Ebisawa, R. Murray, R. Naclerio, Y. Okamoto, D. V. Wallace, and The MASK study group
Subjects: App, Asthma, Care pathways, MASK, mHealth, Rhinitis, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Aims Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors. Results MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018) MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
Published: 2019
Full Text: View/download PDF

5. Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement

Author: P. W. Hellings, B. Pugin, G. Mariën, C. Bachert, C. Breynaert, D. M. Bullens, J. L. Ceuppens, G. Clement, T. Cox, D. Ebo, P. Gevaert, S. Halewyck, V. Hox, K. Ladha, R. Jacobs, P. Rombaux, R. Schrijvers, K. Speleman, X. Van der Brempt, L. Van Gerven, O. Vanderveken, B. Verhaeghe, K. Vierstraete, S. Vlaminck, J. -B. Watelet, J. Bousquet, and S. F. Seys
Subjects: Allergic rhinitis, Asthma, Allergen-specific immunotherapy, Belgium, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Allergic rhinitis (AR) affects 23–30% of the European population with equal prevalence reported in Belgium. Despite guidelines on the correct use of effective treatment, up to 40% of AR patients remain uncontrolled. Allergen immunotherapy (AIT) has been shown to improve the level of control up to 84% of patients being controlled by AIT. Recently, new guidelines for AIT have been published, supporting the clinical evidence for effectiveness of various subcutaneous and sublingual products for AIT in patients who are allergic to airborne allergens. AIT in AR patients not only reduces nasal and/or ocular symptoms but also induces tolerance and has preventive potential. Adoption of AIT into daily clinical practice in Belgium and other European countries is hampered primarily by reimbursement issues of each of the single products but also by several patient- and physician-related factors. Patients need to be better informed about the effectiveness of AIT and the different routes of administration of AIT. Physicians dealing with AR patients should inform patients on tolerance-inducing effects of AIT and are in the need of a harmonized and practical guide that supports them in selecting eligible patients for AIT, in choosing evidence-based AIT products and in following treatment protocols with proven efficacy. Therefore, a stepwise and holistic approach is needed for better adoption of AIT in the real-life setting in Belgium.
Published: 2019
Full Text: View/download PDF

6. Empfehlungen zur Überprüfung der Wirksamkeit und Verlaufsdokumentation von Mepolizumab bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC)

Author: L. Klimek, U. Förster-Ruhrmann, H. Olze, A. G. Beule, A. M. Chaker, J. Hagemann, T. Huppertz, T. K. Hoffmann, S. Dazert, T. Deitmer, S. Strieth, H. Wrede, W. Schlenter, H. J. Welkoborsky, B. Wollenberg, S. Becker, F. Bärhold, F. Klimek, I. Casper, J. Zuberbier, C. Rudack, M. Cuevas, C. A. Hintschich, O. Guntinas-Lichius, T. Stöver, C. Bergmann, P. Werminghaus, O. Pfaar, J. Gosepath, M. Gröger, C. Beutner, M. Laudien, R. K. Weber, T. Hildenbrand, A. S. Hoffmann, and C. Bachert
Subjects: Otorhinolaryngology
Abstract: Zusammenfassung Hintergrund Die chronische Rhinosinusitis mit Nasenpolypen (CRSwNP) ist eine multifaktorielle entzündliche Erkrankung der Schleimhäute von Nase und Nasennebenhöhlen. Eine eosinophile Entzündung wird als häufiger Endotyp beschrieben. Der Anti-IL-5-Antikörper Mepolizumab ist seit November 2021 als Zusatztherapie zu intranasalen Glukokortikosteroiden für die Behandlung Erwachsener mit schwerer chronischer Rhinosinusitis mit Nasenpolypen zugelassen, wenn systemische Glukokortikosteroide oder eine Operation keine ausreichende Krankheitskontrolle bewirken. Während nationale und internationale Empfehlungen für den Einsatz von Mepolizumab bei CRSwNP existieren, ist bislang nicht hinreichend festgelegt worden, wie diese Therapie überwacht wird, welche Folgedokumentation notwendig ist und wann sie ggf. beendet werden sollte. Methoden In einer Literatursuche wurden die bisherigen Daten zur Behandlung der CRSwNP mit Mepolizumab analysiert und die vorhandene Evidenz durch Recherchen in MEDLINE, PubMed sowie den nationalen und internationalen Studien- und Leitlinienregistern und der Cochrane Library ermittelt. Es wurden Humanstudien berücksichtigt, die im Zeitraum bis einschließlich 10/2022 publiziert wurden. Ergebnis Basierend auf der internationalen Literatur und bisherigen Erfahrungen werden von einem Expertengremium Empfehlungen für die Verlaufskontrolle, das Einhalten von Therapieintervallen und eventuelle Therapiepausen sowie eine Beendigung der Therapie bei Anwendung von Mepolizumab für die Indikation CRSwNP im deutschen Gesundheitssystem auf der Grundlage eines Dokumentationsbogens gegeben. Schlussfolgerungen Das Verständnis über die immunologischen Grundlagen der CRSwNP eröffnet neue, nichtoperative Therapieansätze mit Biologika für Patient*innen mit schweren, unkontrollierten Verlaufsformen. Hier geben wir Empfehlungen für die Verlaufskontrolle, das Einhalten von Therapieintervallen, eventuelle Therapiepausen oder eine Beendigung der Therapie bei einer Mepolizumab-Behandlung als Zusatztherapie mit intranasalen Glukokortikosteroiden zur Behandlung von erwachsenen Patient*innen mit schwerer CRSwNP, die mit systemischen Glukokortikosteroiden und/oder chirurgischem Eingriff nicht ausreichend kontrolliert werden kann.
Published: 2023

7. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

Author: J. Bousquet, S. Arnavielhe, A. Bedbrook, M. Bewick, D. Laune, E. Mathieu-Dupas, R. Murray, G. L. Onorato, J. L. Pépin, R. Picard, F. Portejoie, E. Costa, J. Fonseca, O. Lourenço, M. Morais-Almeida, A. Todo-Bom, A. A. Cruz, J. da Silva, F. S. Serpa, M. Illario, E. Menditto, L. Cecchi, R. Monti, L. Napoli, M. T. Ventura, G. De Feo, D. Larenas-Linnemann, M. Fuentes Perez, Y. R. Huerta Villabolos, D. Rivero-Yeverino, E. Rodriguez-Zagal, F. Amat, I. Annesi-Maesano, I. Bosse, P. Demoly, P. Devillier, J. F. Fontaine, J. Just, T. P. Kuna, B. Samolinski, A. Valiulis, R. Emuzyte, V. Kvedariene, D. Ryan, A. Sheikh, P. Schmidt-Grendelmeier, L. Klimek, O. Pfaar, K. C. Bergmann, R. Mösges, T. Zuberbier, R. E. Roller-Wirnsberger, P. Tomazic, W. J. Fokkens, N. H. Chavannes, S. Reitsma, J. M. Anto, V. Cardona, T. Dedeu, J. Mullol, T. Haahtela, J. Salimäki, S. Toppila-Salmi, E. Valovirta, B. Gemicioğlu, A. Yorgancioglu, N. Papadopoulos, E. P. Prokopakis, S. Bosnic-Anticevich, R. O’Hehir, J. C. Ivancevich, H. Neffen, E. Zernotti, I. Kull, E. Melen, M. Wickman, C. Bachert, P. Hellings, S. Palkonen, C. Bindslev-Jensen, E. Eller, S. Waserman, M. Sova, G. De Vries, M. van Eerd, I. Agache, T. Casale, M. Dykewickz, R. N. Naclerio, Y. Okamoto, D. V. Wallace, and MASK study group
Subjects: App, ARIA, Asthma, Care pathways, MASK, mHealth, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app (the Allergy Diary, Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an overview of the methods used in MASK and the key results obtained to date. These include a novel phenotypic characterization of the patients, confirmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary.
Published: 2018
Full Text: View/download PDF

8. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study

Author: D. Samreth, S. Arnavielhe, F. Ingenrieth, A. Bedbrook, G. L. Onorato, R. Murray, R. Almeida, M. A. Mizani, J. Fonseca, E. Costa, J. Malva, M. Morais-Almeida, A. M. Pereira, A. Todo-Bom, E. Menditto, C. Stellato, M. T. Ventura, D. Larenas-Linnemann, J-M. Fuentes-Pérez, Y. R. Huerta-Villalobos, A. A. Cruz, R. Stelmach, J. da Silva, R. Emuzyte, V. Kvedariene, A. Valiulis, I. Annesi-Maesano, I. Bosse, P. Demoly, P. Devillier, J. F. Fontaine, P. Kuna, B. Samolinski, L. Klimek, R. Mösges, O. Pfaar, S. Shamai, M. Bewick, D. Ryan, A. Sheikh, J. M. Anto, V. Cardona, J. Mullol, A. Valero, N. H. Chavannes, W. J. Fokkens, S. Reitsma, R. E. Roller-Wirnsberger, P. V. Tomazic, T. Haahtela, S. Toppila-Salmi, E. Valovirta, M. Makris, N. G. Papadopoulos, E. P. Prokopakis, F. Psarros, B. Gemicioğlu, A. Yorgancioglu, C. Bindslev-Jensen, E. Eller, I. Kull, M. Wickman, C. Bachert, P. W. Hellings, B. Pugin, S. Bosnic-Anticevich, R. E. O’Hehir, V. Kolek, M. Sova, K. Wehner, G. De Vries, M. van Eerd, D. Laune, J. Wittmann, J. Bousquet, P. Poncelet, and the MASK study group
Subjects: Anonymization, App, MASK, Rhinitis, Asthma, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Background Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission’s Article 29 Working Party stated that geolocation information is personal data. To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method. Methods Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November 2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise addition (randomization) and k-anonymity (generalization). Results Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58.5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity using MASK data to protect the users’ life privacy. Discussion k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for other databases.
Published: 2018
Full Text: View/download PDF

9. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management

Author: C. Bachert, J. Bousquet, and P. Hellings
Subjects: Allergic rhinitis, MP-AzeFlu, Nasal hyperreactivity, Onset of action, Real life, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Background This article summarizes a EUFOREA symposium, presented during the European Rhinology Research Forum in Brussels (9–10 November 2017; https://www.rhinologyresearch.eu/) which focused on novel pathways and therapeutic approaches in allergic rhinitis (AR). Main body AR remains under-diagnosed, under-estimated and under-treated. A key component in understanding the AR landscape has been the realization of a significant mismatch between how physicians instruct AR patients to manage their disease and what AR patients actually do in real life. Data from the Allergy Diary (developed by MACVIA ARIA) showed that AR patients take their medication prn, rapidly switch treatments, often experience poor control, use multiple therapies and stop treatment when symptoms are controlled. Better control of AR may be achievable by using an AR treatment which has a rapid onset of action and which effectively targets breakthrough symptoms. Indeed, AR patients report complete symptom relief, lack of breakthrough symptoms, rapid onset of action, safety and use on an ‘as needed’ basis as key targets for new nasal sprays. MP-AzeFlu comprises intranasal azelastine and fluticasone propionate (FP) in a novel formulation delivered in a single device. It is the first AR treatment to break the 5 min onset of action threshold and provides clinically relevant symptom relief in 15 min, much faster than that noted for FP + oral loratadine. MP-AzeFlu also significantly reduces nasal hyperresponsiveness (NHR) which may be responsible for the breakthrough symptoms frequently reported by AR patients. Mechanisms underlying MP-AzeFlu’s effect include inhibition of mast cell degranulation, stabilization of the mucosal barrier, synergistic inhibition of inflammatory cell recruitment and a unique desensitization of sensory neurons expressing the transient receptor potential A1 and V1 channels. Conclusion With the most rapid onset of action and onset of clinically-relevant effect of any AR medication currently available, and proven efficacy in the treatment of NHR, MP-AzeFlu is an AR treatment which provides what patients want, and fits how patients manage their AR in real life.
Published: 2018
Full Text: View/download PDF

10. ІНТЕГРОВАНІ СХЕМИ МЕДИЧНОЇ ДОПОМОГИ ДЛЯ ПРОГНОСТИЧНОЇ МЕДИЦИНИ ПРОТЯГОМ ЖИТТЄВОГО ЦИКЛУ (ПРОГРАМНИЙ ДОКУМЕНТ 'ARIA – 2016')

Author: V. Вarzylovich, V. Chopiak, I. Gogunskaya, L. Iashyna, I. Kaidashev, T. Umanets, D. Zabolotna, S. Zaikov, I. Agache, C. Bachert, A. Bedbrook, G. Canonica, T. Casale, A. Cruz, W. Fokkens, P. Hellings, B. Samolinski, and J. Bousquet
Subjects: aria, риніт, ікт, eip з aha, мобільні технології, airways icps, Medicine, Ecology, QH540-549.5
Abstract: Ініціатива “Алергічний риніт і його вплив на астму” (“Allergic Rhinitis and its Impact on Asthma” − ARIA) була започаткована під час семінару Всесвітньої організації охорони здоров'я (ВООЗ) в 1999 році. Початкові цілі були: (I) запропонувати нову класифікацію алергічного риніту, (II) розвинути концепцію супутніх захворювань при астмі та риніті і (III) розробити керівні принципи для зацікавлених сторін з метою глобального використання в усіх країнах і групах населення. Проект ARIA − поширений і впроваджений в більш ніж 70 країнах світу, − в даний час зосереджується на застосуванні нових технологій для розвитку індивідуалізованої і прогностичної медицини. Сигнальна мережа “MASK” (MACVIA (Contre les MAladies Chroniques pour un VIeillissement Actif)-ARIA Sentinel NetworK) використовує мобільні технології для розробки схем медичної допомоги, з тим щоб досягти лікування риніту та астми багатопрофільної групою спеціалістів або самими пацієнтами. Додаток (Android і IOS) доступний в 20 країнах на 15 мовах світу. У ньому використовується візуальна аналогова шкала для оцінки контролю симптомів і продуктивності праці, а також клінічна система підтримки прийняття рішень. Додаток інтегровано в планшети, що уможливлюють співпрацю з лікарями та іншими медичними працівниками. Стратегія розширення масштабів заснована на рекомендаціях Європейського інноваційного партнерства з активного і здорового старіння. Мета новітнього підходу ARIA полягає в тому, щоб забезпечити активний і здоровий спосіб життя пацієнтів з ринітом, незалежно від їх віку, статі чи соціально-економічного статусу, тим самим подолавши соціальну нерівність у сфері охорони здоров'я, що виникає в результаті цієї хвороби.
Published: 2017

11. ENGLISH VERSION: INTEGRATED CARE PATHWAYS FOR PREDICTIVE MEDICINE ACROSS THE LIFE CYCLE (ARIA – 2016 EXECUTIVE SUMMARY)

Author: V. Вarzylovich, V. Chopiak, I. Gogunskaya, L. Iashyna, I. Kaidashev, T. Umanets, D. Zabolotna, S. Zaikov, I. Agache, C. Bachert, A. Bedbrook, G. Canonica, T. Casale, A. Cruz, W. Fokkens, P. Hellings, B. Samolinski, and J. Bousquet
Subjects: aria, rhinitis, ict, eip on aha, mobile technology, airways icps, Medicine, Ecology, QH540-549.5
Abstract: The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization (WHO) workshop in 1999. The initial goals were (i) to propose a new allergic rhinitis classification, (ii) to promote the concept of multi-morbidity in asthma and rhinitis and (iii) to develop guidelines with all stakeholders for global use in all countries and populations. ARIA ‒ disseminated and implemented in over 70 countries globally ‒ is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK (MACVIA (Contre les MAladies Chroniques pour un VIeillissement Actif)-ARIA Sentinel NetworK) uses mobile technology to develop care pathways in order to enable the management of rhinitis and asthma by a multi-disciplinary group or by patients themselves. An App (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
Published: 2017

12. Empfehlungen zur Überprüfung der Wirksamkeit und Verlaufsdokumentation von Dupilumab bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) im deutschen Gesundheitssystem

Author: L. Klimek, U. Förster-Ruhrmann, H. Olze, A. G. Beule, A. M. Chaker, J. Hagemann, T. Huppertz, T. K. Hoffmann, S. Dazert, T. Deitmer, S. Strieth, H. Wrede, W. Schlenter, H. J. Welkoborsky, B. Wollenberg, S. Becker, F. Klimek, A. Sperl, I. Casper, J. Zuberbier, C. Rudack, M. Cuevas, C. A. Hintschich, O. Guntinas-Lichius, T. Stöver, C. Bergmann, O. Pfaar, J. Gosepath, M. Gröger, C. Beutner, M. Laudien, R. K. Weber, T. Hildenbrand, A. S. Hoffmann, and C. Bachert
Subjects: Otorhinolaryngology
Abstract: Zusammenfassung Hintergrund Die chronische Rhinosinusitis mit Nasenpolypen (CRSwNP) ist eine multifaktorielle entzündliche Erkrankung der Schleimhäute von Nase und Nasennebenhöhlen. Eine Typ-2-Inflammation als immunologischer Mechanismus wird als häufigster Endotyp beschrieben. Der Anti-IL-4-/-IL-13-Antikörper Dupilumab ist seit Oktober 2019 als Zusatztherapie zu intranasalen Glukokortikosteroiden für die Behandlung Erwachsener mit schwerer chronischer Rhinosinusitis mit Nasenpolypen zugelassen, wenn systemische Glukokortikosteroide oder eine Operation keine ausreichende Krankheitskontrolle bewirken. Während nationale und internationale Empfehlungen für den Einsatz von Dupilumab bei CRSwNP existieren, ist bislang nicht hinreichend festgelegt worden, wie diese Therapie überwacht und wann sie ggf. beendet werden sollte. Methoden In einer Literatursuche wurden die bisherigen Daten zur Behandlung der CRSwNP mit Dupilumab analysiert und die vorhandene Evidenz durch Recherchen in MEDLINE, PubMed sowie den nationalen und internationalen Studien- und Leitlinienregistern und der Cochrane Library ermittelt. Es wurden Humanstudien berücksichtigt, die im Zeitraum bis einschließlich 05/2022 publiziert wurden. Ergebnis Basierend auf der internationalen Literatur und bisherigen Erfahrungen werden von einem Expertengremium Empfehlungen für die Verlaufskontrolle, das Einhalten von Therapieintervallen und eventuelle Therapiepausen sowie eine Beendigung der Therapie bei Anwendung von Dupilumab für die Indikation CRSwNP im deutschen Gesundheitssystem auf der Grundlage eines Dokumentationsbogens gegeben. Schlussfolgerungen Das Verständnis über die immunologischen Grundlagen der CRSwNP eröffnet neue nichtoperative Therapieansätze mit Biologika für Patienten mit schweren, unkontrollierten Verlaufsformen. Wir geben hier Empfehlungen für die Verlaufskontrolle, das Einhalten von Therapieintervallen, eventuelle Therapiepausen oder eine Beendigung der Therapie bei einer Dupilumab-Behandlung als Zusatztherapie mit intranasalen Glukokortikosteroiden zur Behandlung von erwachsenen Patienten mit schwerer CRSwNP, die mit systemischen Glukokortikosteroiden und/oder chirurgischem Eingriff nicht ausreichend kontrolliert werden können.
Published: 2022

13. A herbal composition of Scutellaria baicalensis and Eleutherococcus senticosus shows vasocontrictive effects in an ex-vivo mucosal tissue model and in allergic rhinitis patients

Author: Michael Katotomichelakis, K. Van Crombruggen, G. Holtappels, F. A. Kuhn, C. E. Fichandler, C. A. Kuhn-Glendye, J. B. Anon, C. T. Melroy, B. Karanfilov, T. W. Haegen, I. Kastanioudakis, C. Bachert, and N. Zhang
Subjects: Herbal treatment, Scutellaria Baicalensis, Eleuthrococcus senticosus, Nasal congestion, Smell, Medicine, Homeopathy, RX1-681
Abstract: Abstract Background This study aimed to investigate the nasal decongestive efficacy of an alternative to pharmacotherapy, a herbal nasal spray composed of Scutellaria baicalensis and Eleutherococcus senticosus. Methods Scutellaria baicalensis and Eleuthrococcus senticosus and control solutions were applied separately to isolated mucosal tissue from inferior turbinates. Vasoconstriction was measured as a change in isometric tension. Moreover, twenty allergic rhinitis patients with nasal stuffiness participated in a randomized, placebo-controlled clinical study with cross-over design; the same patients served as their placebo control group. Pre-and post-treatment nasal congestion and smell test scores were evaluated for the test and placebo spray using two validated questionnaires, the 5 question nasal congestion questionnaire and the 12 question Brief Smell Identification Test-Version B. Results In the ex-vivo mucosal tissue, the herbal compounds were demonstrated to induce vasoconstriction when applied at 10 mg/ml concentration. The combination of S. baicalensis and E. senticosus proved effective in relieving patients’ nasal congestion and was statistically superior to placebo. No side effects were noted, and there was no difference between the pre-and post-study smell test results. Conclusions The combined S. baicalensis and E. senticosus herbal nasal spray relieved nasal congestion significantly better than placebo without any side effects.
Published: 2017
Full Text: View/download PDF

14. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

Author: J. Bousquet, G. L. Onorato, C. Bachert, M. Barbolini, A. Bedbrook, L. Bjermer, J. Correia de Sousa, N. H. Chavannes, A. A. Cruz, E. De Manuel Keenoy, P. Devillier, J. Fonseca, S. Hun, T. Kostka, P. W. Hellings, M. Illario, J. C. Ivancevich, D. Larenas-Linnemann, J. Millot-Keurinck, D. Ryan, B. Samolinski, A. Sheikh, A. Yorgancioglu, I. Agache, S. Arnavielhe, M. Bewick, I. Annesi-Maesano, J. M. Anto, K. C. Bergmann, C. Bindslev-Jensen, S. Bosnic-Anticevich, J. Bouchard, D. P. Caimmi, P. Camargos, G. W. Canonica, V. Cardona, A. M. Carriazo, C. Cingi, E. Colgan, A. Custovic, R. Dahl, P. Demoly, G. De Vries, W. J. Fokkens, J. F. Fontaine, B. Gemicioğlu, N. Guldemond, Z. Gutter, T. Haahtela, B. Hellqvist-Dahl, E. Jares, G. Joos, J. Just, N. Khaltaev, T. Keil, L. Klimek, M. L. Kowalski, I. Kull, P. Kuna, V. Kvedariene, D. Laune, R. Louis, A. Magnan, J. Malva, E. Mathieu-Dupas, E. Melén, E. Menditto, M. Morais-Almeida, R. Mösges, J. Mullol, R. Murray, H. Neffen, R. O’Hehir, S. Palkonen, N. G. Papadopoulos, G. Passalacqua, J. L. Pépin, F. Portejoie, D. Price, B. Pugin, F. Raciborski, F. E. R. Simons, M. Sova, O. Spranger, C. Stellato, A. Todo Bom, P. V. Tomazic, M. Triggiani, A. Valero, E. Valovirta, O. VandenPlas, A. Valiulis, M. van Eerd, M. T. Ventura, M. Wickman, I. Young, T. Zuberbier, A. Zurkuhlen, and A. Senn
Subjects: Rhinitis, Asthma, CHRODIS, ARIA, MASK, Sunfrail, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.
Published: 2017
Full Text: View/download PDF

15. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report

Author: C. Cingi, P. Gevaert, R. Mösges, C. Rondon, V. Hox, M. Rudenko, N. B. Muluk, G. Scadding, F. Manole, C. Hupin, W. J. Fokkens, C. Akdis, C. Bachert, P. Demoly, J. Mullol, A. Muraro, N. Papadopoulos, R. Pawankar, P. Rombaux, E. Toskala, L. Kalogjera, E. Prokopakis, P. W. Hellings, and J. Bousquet
Subjects: Adenoid hypertrophy, Allergic rhinitis (AR), Asthma, Chronic middle ear effusions, Comorbidities, Disordered sleep, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract This report has been prepared by the European Academy of Allergy and Clinical Immunology Task Force on Allergic Rhinitis (AR) comorbidities. The aim of this multidisciplinary European consensus document is to highlight the role of multimorbidities in the definition, classification, mechanisms, recommendations for diagnosis and treatment of AR, and to define the needs in this neglected area by a literature review. AR is a systemic allergic disease and is generally associated with numerous multi-morbid disorders, including asthma, eczema, food allergies, eosinophilic oesophagitis (EoE), conjunctivitis, chronic middle ear effusions, rhinosinusitis, adenoid hypertrophy, olfaction disorders, obstructive sleep apnea, disordered sleep and consequent behavioural and educational effects. This report provides up-to-date usable information to: (1) improve the knowledge and skills of allergists, so as to ultimately improve the overall quality of patient care; (2) to increase interest in this area; and (3) to present a unique contribution to the field of upper inflammatory disease.
Published: 2017
Full Text: View/download PDF

16. The management of chronic rhinosinusitis with nasal polyps (CRSwNP) with biologics

Author: A. Wautlet, C. Bachert, M. Desrosiers, P. Hellings, and Anju T. Peters
Subjects: Immunology and Allergy
Published: 2023

17. Positionspapier: Empfehlungen zur Anwendung von Mepolizumab bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC)

Author: L. Klimek, H. Olze, U. Förster-Ruhrmann, A. G. Beule, A. M. Chaker, J. Hagemann, T. Huppertz, T. K. Hoffmann, S. Dazert, T. Deitmer, S. Strieth, H. Wrede, W. Schlenter, H. J. Welkoborsky, B. Wollenberg, S. Becker, F. Klimek, J. Zuberbier, C. Rudack, M. Cuevas, C. A. Hintschich, O. Guntinas-Lichius, T. Stöver, C. Bergmann, and C. Bachert
Subjects: Otorhinolaryngology
Abstract: Zusammenfassung Hintergrund Die chronische Rhinosinusitis mit Nasenpolypen (CRSwNP) ist eine multifaktorielle entzündliche Erkrankung der paranasalen Schleimhäute, der als häufigstem Endotyp eine eosinophile Inflammation zugrunde liegt. Der Anti-IL-5-Antikörper Mepolizumab wurde im November 2021 für die Therapie der schweren CRSwNP zugelassen. Methoden In einer Literatursuche wurde die Immunologie der CRSwNP analysiert und die vorhandene Evidenz ermittelt durch Recherchen in Medline, PubMed sowie den nationalen und internationalen Studien- und Leitlinien-Registern und der Cochrane Library. Es wurden Humanstudien berücksichtigt, die bis einschließlich 12/2021 publiziert wurden und in denen die Wirkung von Mepolizumab bei CRSwNP untersucht wurde. Ergebnis Basierend auf der internationalen Literatur und bisherigen Erfahrungen werden von einem Expertengremium Empfehlungen für die Anwendung von Mepolizumab bei CRSwNP im deutschen Gesundheitssystem auf der Grundlage eines Dokumentationsbogens gegeben. Schlussfolgerungen Das Verständnis über die immunologischen Grundlagen der CRSwNP eröffnet neue nichtoperative Therapieansätze mit Biologika für Patienten mit schweren Verlaufsformen. Mepolizumab ist seit November 2021 zugelassen zur Zusatztherapie mit intranasalen Kortikosteroiden zur Behandlung von erwachsenen Patienten mit schwerer CRSwNP, die mit systemischen Kortikosteroiden und/oder chirurgischem Eingriff nicht ausreichend kontrolliert werden können.
Published: 2022

18. INFERRING ROOF SEMANTICS FOR MORE ACCURATE SOLAR POTENTIAL ASSESSMENT

Author: Ö. Tufan, O. Veselý, C. Bachert, I. Apra, E. Verbree, and C. Cáceres Tocora
Subjects: Technology, 3D city models, business.industry, Computer science, AHN3, Roof, Obstacle, Solar potential, Energy transition, Engineering (General). Civil engineering (General), Semantics, Solar energy, Construction engineering, TA1501-1820, Renewable energy, Detection, Lidar, Aerial photography, Machine learning, Applied optics. Photonics, TA1-2040, business
Abstract: In guiding the energy transition efforts towards renewable energy sources, 3D city models were shown to be useful tools when assessing the annual solar energy generation potential of urban landscapes. However, the simplified roof geometry included in these 3D city models and the lack of additional semantic information about the buildings’ roof often yield less accurate solar potential evaluations than desirable. In this paper we propose three different methods to infer and store additional information into 3D city models, namely on physical obstacles present on the roof and existing solar panels. Both can be used to increase the accuracy of roof solar panel retrofit potential. These methods are developed and tested on the open datasets available in the Netherlands, specifically AHN3 lidar point-cloud and PDOK aerial photography. However, we believe they can be adapted to different environments as well, based on the available datasets and their precision locally available.
Published: 2021

19. Onset, Maintenance, and Durability of Response with Dupilumab in Chronic Rhinosinusitis with Nasal Polyps

Author: C Bachert, A Khan, W Fokkens, C Hopkins, P Gevaert, J Han, P Hellings, S Lee, J Msihid, S Nash, S Siddiqui, J Jacob-Nara, Y Deniz, and P Rowe
Published: 2022

20. Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP

Author: C, Bachert, P W, Hellings, V J, Lund, W J, Fokkens, C, Hopkins, B, Mayer, R H, Chan, S G, Smith, A R, Sousa, R, Alfonso-Cristancho, S, Yang, On Behalf Of The Synapse Study Group, On Behalf Of The Synapse Study Group, Ear, Nose and Throat, and AII - Inflammatory diseases
Subjects: Science & Technology, Otorhinolaryngology, Quality of Life, Humans, NASAL POLYPS, CHRONIC RHINOSINUSITIS, General Medicine, Antibodies, Monoclonal, Humanized, Life Sciences & Biomedicine
Abstract: Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP. ispartof: RHINOLOGY vol:60 issue:6 ispartof: location:Netherlands status: published
Published: 2022

21. Association between outdoor air pollution and chronic rhinosinusitis patient outcomes

Author: S. Peeters, C. Wang, E.M. Bijnens, D.M.A. Bullens, W.J. Fokkens, C. Bachert, P.W. Hellings, T.S. Nawrot, and S.F. Seys
Abstract: Background: The aetiology of chronic rhinosinusitis (CRS) is multifactorial with a complex interplay between environmental, microbial endogenous and genetic factors. The impact of outdoor air pollution on prevalence or severity of CRS remains largely unknown. Methods: Real-life geolocation data (2017-2018, Belgium) from 278 CRS patients (2576 health records) using the mySinusitisCoach mobile application were analysed to calculate the patients’ individual exposure to outdoor air pollutants (ozone (O3), black carbon (BC), nitrogen dioxide (NO2) and particulate matter with diameter 2.5)) and associate these pollutants with the patients’ sinus related symptoms measured at multiple occasions by visual analogue scale (VAS).Results: The adjusted seasonal model for the spring-summer (n=1000 health entries, N=83 patients) population revealed an increase of 6.07 (p3 (26.9 μg/m3). An increase of 1.69 (p=0.05) in total CRS symptom scoring was observed for an IQR increase of PM2.5 (7.1 µg/m3) exposure. Gender-stratified analysis in the spring-summer population showed significant interaction between air pollution and gender with male patients having higher total CRS symptom scores for an IQR increase in exposure to PM2.5 (3.52, p=0.001), and O3 (8.33, p2.5 (2.58, p=0.04) and O3 (7.72, pConclusion: Exposure to outdoor air pollution is associated with increased symptom severity in CRS patients. The extent to which CRS patients are sensitive to outdoor air pollution exposure varies per season and depends on their gender and comorbid asthma status. mHealth technology has the potential to reveal novel insights on the patients’ exposome and disease severity in the real-life situation.
Published: 2022

22. DUPILUMAB IMPROVES CHRONIC RHINOSINUSITIS WITH NASAL POLYPS DISEASE OUTCOMES IRRESPECTIVE OF TYPE 2 SIGNATURE DEFINITION

Author: C. Bachert, A. Khan, S. Lee, A. Peters, S. Nash, A. Radwan, and J. Jacob-Nara
Subjects: Pulmonary and Respiratory Medicine, Immunology, Immunology and Allergy
Published: 2022

23. Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC)

Author: L. Klimek, U. Förster-Ruhrmann, S. Becker, A. Chaker, S. Strieth, T. K. Hoffmann, S. Dazert, T. Deitmer, H. Olze, A. Glien, S. Plontke, H. Wrede, W. Schlenter, H. J. Welkoborsky, B. Wollenberg, A. G. Beule, C. Rudack, M. Wagenmann, T. Stöver, T. Huppertz, J. Hagemann, and C. Bachert
Subjects: 03 medical and health sciences, 0302 clinical medicine, Otorhinolaryngology, 030223 otorhinolaryngology
Abstract: Zusammenfassung Hintergrund Die chronische Rhinosinusitis (CRS) betrifft weltweit ca. 5–12 % der Allgemeinbevölkerung und wird traditionell eingeteilt in einen Phänotyp ohne (CRSsNP) und einen mit Ausbildung von Nasenpolypen (CRSwNP). Wurden Nasenpolypen bis vor kurzem eher als mechanisches Hindernis mit der Notwendigkeit einer operativen Beseitigung betrachtet, wird die CRSwNP heute als eine multifaktorielle entzündliche Erkrankung der nasalen und paranasalen Schleimhäute angesehen, der als Endotyp häufig eine T2-Inflammation zugrunde liegt. Biologika, die mit diesen Entzündungsmechanismen interferieren, stellen interessante neue Therapiemöglichkeiten dar. Methoden Das aktuelle Wissen zur Immunologie der CRSwNP und Wirkung von Biologika wurde mittels einer Literaturanalyse durch Recherchen in Medline, PubMed sowie den nationalen und internationalen Studien- und Leitlinienregistern und der Cochrane Library zusammengestellt. Ergebnisse Basierend auf der internationalen Literatur und bisherigen Erfahrungen werden von einem Expertengremium Empfehlungen für die Anwendung von Biologika bei CRSwNP im deutschen Gesundheitssystem auf der Grundlage eines Dokumentationsbogens gegeben. Schlussfolgerung Das Verständnis über die immunologischen Grundlagen der CRSwNP eröffnet neue nichtoperative Therapieansätze mit Biologika für Patienten mit schweren Verlaufsformen.
Published: 2020

24. Impact de mépolizumab sur le sommeil chez les patients avec polypose nasosinusienne (PNS) : les données de l’étude SYNAPSE

Author: J. Mullol, C. Bachert, W. Fokkens, S.G. Smith, T. Keeley, B. Mayer, P. Howarth, R. Chan, S. Yancey, and L. Iaz-Chachuat
Subjects: Pulmonary and Respiratory Medicine
Published: 2023

25. Allergen Immunotherapy (AIT): a prototype of Precision Medicine

Author: GW Canonica, C. Bachert, P. Hellings, D. Ryan, E. Valovirta, M. Wickman, O. De Beaumont, and J. Bousquet
Subjects: Immunologic diseases. Allergy, RC581-607
Abstract: Precision medicine is a medical model aiming to deliver customised healthcare - with medical decisions, practices, and/or products tailored to the individual patient informed but not directed by guidelines. Allergen immunotherapy has unique immunological rationale, since the approach is tailored to the specific IgE spectrum of an individual and modifies the natural course of the disease as it has a persistent efficacy after completion of treatment. In this perspective Allergen Immunotherapy - AIT has to be presently considered a prototype of Precision Medicine.Precise information and biomarkers provided by systems medicine and network medicine will address the discovery of Allergen immunotherapy biomarkers for (i) identification of the causes, (ii) stratification of eligible patients for AIT and (iii) the assessment of AIT efficacy.This area of medical technology is evolving rapidly and, compelemented by e-health, will change the way we practice medicine. It will help to monitor patients’ disease control and data for (i) patient stratification, (ii) clinical trials, (iii) monitoring the efficacy and safety of targeted therapies which are critical for reaching an appropriate reimbursement. Biomarkers associated with e-health combined with a clinical decision support system (CDSS) will change the scope of Allergen immunotherapy.The cost/effectiveness of Allergen immunotherapy is a key issue for successful implementation. It should include the long-term benefits in the pharmaco-economic evaluation, since no other allergy treatment has this specific characteristic.AIT is the prototype of current and future precision medicine. Keywords: Allergen immunotherapy, AIT, Precision medicine, Personalized medicine, Allergy
Published: 2015
Full Text: View/download PDF

26. Endotyp-orientierte Behandlungspfade bei chronischer Rhinosinusitis

Author: C. Bachert and N. Zhang
Subjects: 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, business.industry, Immunology and Allergy, Medicine, 030223 otorhinolaryngology, business
Published: 2018

27. Association Between Dupilumab Effect on Nasal Polyp Score and Biomarkers of Type 2 Inflammation in Patients with Chronic Rhinosinusitis with Nasal Polyps in the Phase 3 SINUS-24 and SINUS-52 Trials

Author: C. Bachert, J. Corren, S.E. Lee, H. Zhang, S. Harel, D. Cunoosamy, A.H. Khan, J.A. Jacob-Nara, S. Siddiqui, and S. Nash
Published: 2021

28. La sensibilisation à l’entérotoxine du Staphylococcus aureus et la réponse à l’omalizumab chez les patients asthmatiques sévères atopiques et non atopiques

Author: N. Migueres, A. Poirot, N. Zhang, C. Bachert, and F. De Blay
Subjects: Immunology and Allergy
Published: 2022

29. Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement

Author: K., Scadding Glenis, W., Hellings Peter, C., Bachert, L., Bjermer, Z., Diamant, P., Gevaert, A., Kjeldsen, J., Kleine-Tebbe, L., Klimek, A., Muraro, G., Roberts, A., Steinsvik, M., Wagenmann, and U., Wahn
Published: 2020
Full Text: View/download PDF

30. 2020 ARIA CARE PATHWAYS FOR ALLERGIC RHINITIS - GEORGIA

Author: M, Gotua, A, Gamkrelidze, M, Rukhadze, T, Abramidze, E, Bochorishvili, G, Shengelidze, N, Dolidze, E, Chkhartishvili, C, Bachert, O, Pfaar, H J, Schünemann, T, Zuberbier, A, Bedbrook, W, Czarlewski, and J, Bousquet
Subjects: Rhinitis, Allergic, Perennial, Desensitization, Immunologic, Humans, Georgia (Republic), Rhinitis, Allergic, Asthma
Abstract: Allergic rhinitis is the most common chronic disease worldwide. Treatment guidelines have improved the knowledge on rhinitis and have had a significant impact on AR management. In 20 years, ARIA has considerably evolved from the first multi-morbidity guideline in respiratory diseases to the digital transformation of health and care. Allergic rhinitis in Georgia, Next-generation ARIA-GRADE guidelines and ARIA, 2020 care pathways for Allergen Immunotherapy have been discussed in this review.
Published: 2020

31. EUFOREA Rhinology Research Forum 2017: report of the brainstorming sessions on endotype-driven treatment, patient empowerment and digital future in airways care

Author: I. Koren, K. Talavera-Perez, J.A. Castillo, Valerie J. Lund, N.S. Seyed-Tabib, J.A.M. Claes, Ruth Murray, M. Koennecke, B Lange, C. Bachert, K. Sleurs, G. De Carlo, Guy Joos, I. Kortekaas-Krohn, A. Van Hoolst, M. Akdis, S.K. Chung, R. Boscke, C. Akdis, Ph. Rombaux, B. Verhaeghe, Maria Doulaptsi, S. Vaitkus, D. O'Sullivan, T. Zuberbier, Sven Seys, Benoit Pugin, V. Boeva, P. Gevaert, Brecht Steelant, J. Staikuniene, K. Golebski, C. Rondon, S. Gallo, Michel Djandji, A.-J. Tasman, J. Lee, J. Feijen, I. Kloeck, G.W. Canonica, J Mullol, C. Taube, W.J. Fokkens, A. Jagerschmidt, T.A. Popov, Sanna Toppila-Salmi, T. Tran-Le, S Vlaminck, Jean Bousquet, K. van Gool, G.Y. Ban, K. Biswas, Claire Hopkins, J. Vaitkus, Anette Drøhse Kjeldsen, Simon B. Gane, Olga Krysko, Leen Cools, Kato Speleman, R. Verbrugge, Martin Wagenmann, Thomas Hummel, O. Kokorina, E. De Corso, P W Hellings, D. Morghenti, Katleen Martens, Emmanuel P. Prokopakis, Carl Philpott, I. Izquierdo, Leda Mannent, S. Halewyck, N. Launders, L. Van Gerven, Basile Nicolas Landis, P.J. Rowe, G. Lekakis, Ear, nose & throat, and Ear, Nose and Throat
Subjects: Rhinology, medicine.medical_specialty, Medical education, Endotype, business.industry, Patient Empowerment, ehealth, precision medicine, education, General Medicine, Precision medicine, patient empowerment, rhinitis, Otorhinolaryngology, RF1-547, Brainstorming, medicine, eHealth, endotype, business, rhinosinusitis, health care economics and organizations
Abstract: The second European Rhinology Reserach Forum organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) was held on 9-10th November 2017, combined with a specific symposium on air pollution and mobile Health technology (mHealth) with the GARD (Global Alliance against Chronic Respiratory Diseases) initiative of WHO (World Health Organization). Physicians from different specialities, researchers, as well as patients and industry representatives from more than 40 countries took part in the Forum. Relevant topics were debated with the aim of allowing the implementation of precision medicine (PM) in daily respiratory care. All debates started with positioning the current state of the art: identification of current gaps in practice, the current consensus and the need for implementation of novel approaches such as endotype-driven treatment, patient empowerment and eHealth tools. This report provides a summry of the outcomes of the brainstorming sessions of the European Rhinology Research Forum 2017, highlighting the research needs in PM, with personalized care, prediction of success of treatment, participation of the patient and prevention of disease as key drivers for improving current clinical practice.
Published: 2018

32. Dupilumab 临床试验中的结膜炎

Author: B. Akinlade, E. Guttman‐Yassky, M. Bruin‐Weller, E.L. Simpson, A. Blauvelt, M.J. Cork, E. Prens, P. Asbell, E. Akpek, J. Corren, C. Bachert, I. Hirano, J. Weyne, A. Korotzer, Z. Chen, T. Hultsch, X. Zhu, J.D. Davis, L. Mannent, J.D. Hamilton, A. Teper, H. Staudinger, E. Rizova, G. Pirozzi, N.M.H. Graham, B. Shumel, M. Ardeleanu, and A. Wollenberg
Subjects: Dermatology
Published: 2019

33. Aandoeningen van de neusbijholten

Author: C. Bachert, T. Van Zele, N. de Vries, de Vries, N., Van de Heyning, P.H., and Leemans, C.R.
Published: 2019

34. Zur Diskussion gestellt: Wirksamkeit spezifischer Immuntherapeutika – die S2k-Leitlinie im Fokus. Ergänzende Betrachtung auf Basis der Wirksamkeitskriterien nach WAO- und EMA

Author: A. Horn and C. Bachert
Subjects: 03 medical and health sciences, 0302 clinical medicine, business.industry, 030503 health policy & services, Immunology and Allergy, Medicine, 030212 general & internal medicine, 0305 other medical science, business
Published: 2016

35. Zur Diskussion gestellt: Der Arzt und die Spezifische Immuntherapie im Spannungsfeld von Leitlinie, Wirtschaftlichkeit und Medizinrecht

Author: C. Bachert and K. Gräfin von Strachwitz-Helmstatt
Subjects: 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, business.industry, Immunology and Allergy, Medicine, business
Published: 2016

36. 鼻茸を伴う慢性副鼻腔炎を対象とするDupilumab第3相試験：全身性ステロイド薬の使用度と手術減少

Author: M Desrosiers, C Bachert, J Han, S Lee, X Mao, M Zhang, N Amin, N Patel, N Graham, M Ruddy, H Staudinger, and L Mannent
Published: 2020

37. Fully integrated Q-switch for commercial high-power resonator with solitary XLMA-fiber

Author: Oliver Fitzau, H. Enns, Hans-Dieter Hoffmann, S. Hosdorf, R. Luxen, M. Bay, V. Krause, M. Giesberts, R. Lange, S. Marfels, C. Bachert, G. Rehmann, M. Schenk, A. Kösters, and H. Weber
Subjects: Ytterbium, Materials science, business.industry, Amplifier, chemistry.chemical_element, Laser, law.invention, Resonator, Optics, Double-clad fiber, chemistry, law, Fiber laser, Continuous wave, Laser power scaling, business
Abstract: In surface processing applications the correlation of laser power to processing speed demands a further enhancement of the performance of short-pulsed laser sources with respect to the investment costs. The frequently applied concept of master oscillator power amplifier relies on a complex structure, parts of which are highly sensitive to back reflected amplified radiation. Aiming for a simpler, robust source using only a single ytterbium doped XLMA fiber in a q-switched resonator appears as promising design approach eliminating the need for subsequent amplification. This concept requires a high power-tolerant resonator which is provided by the multikilowatt laser platform of Laserline including directly water-cooled active fiber thermal management. Laserline GmbH and Fraunhofer Institute for Laser Technology joined their forces1 to upgrade standard high power laser sources for short-pulsed operation exceeding 1 kW of average power. Therefor a compact, modular qswitch has been developed. In this paper the implementation of a polarization independent q-switch into an off-the-shelf multi-kilowatt diodepumped continuous wave fiber source is shown. In this early step of implementation we demonstrated more than 1000 W of average power at pulse lengths below 50 ns FWHM and 7.5 mJ pulse energy. The M2 corresponds to 9.5. Reliability of the system is demonstrated based on measurements including temperature and stability records. We investigated the variation possibilities concerning pulse parameters and shape as well as upcoming challenges in power up-scaling.
Published: 2018

38. Directly q-switched high power resonator based on XLMA-fibers

Author: M. Giesberts, C. Bachert, V. Krause, Oliver Fitzau, Hans-Dieter Hoffmann, and R. Lange
Subjects: Materials science, business.industry, 02 engineering and technology, Nanosecond, 01 natural sciences, Pockels effect, Power (physics), 010309 optics, Wavelength, Resonator, 020210 optoelectronics & photonics, Fiber laser, 0103 physical sciences, 0202 electrical engineering, electronic engineering, information engineering, Optoelectronics, M squared, A fibers, business
Abstract: In this paper we present a simple approach to achieving nanosecond pulses from a directly q-switched high-power resonator based on extra-large mode area (XLMA) fibers with a beam quality factor M2 500 W has been demonstrated for repetition frequencies between 50-100 kHz. The resonator consists of a single fiber q-switched with soldered Pockels-cells which exhibit a very high contrast ratio leading to output pulses down to about 10 ns and peak powers up to > 250 kW at 1064 nm wavelength. By using this design instead of a fiber MOPA setup, a cost-effective and less complex system could be implemented.
Published: 2018

39. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

Author: Karin C. Lødrup Carlsen, L. Cecchi, F. Portejoie, T. Vontetsianos, Olivier Vandenplas, M. van Hague, D. Mora Bogado, M. Illario, Dana Wallace, L. Namazova-Baranova, E. Asayag, I. Ribeirinho, E. Costa, Shona Pedersen, Inger Kull, Davor Plavec, M. Morais-Almeida, Mickael Bewick, N.H. Chavannes, I. J. Ansotegui, G. De Carlo, K. S. Bennoor, Faradiba Sarquis Serpa, S. Arnavielle, F. Corti, Moises A. Calderon, Martín Bedolla-Barajas, Mette Sørensen, Isabella Annesi-Maesano, Elaine Colgan, Przemyslaw Kardas, M. van Eerd, Jorge Maspero, Valérie Siroux, Isabelle Momas, Ralph Mösges, Yves Dauvilliers, T. Keil, T. Bieber, Marit Westman, Rachel Nadif, O. Pfaar, A.C. Carvalho Coehlo, R. M. Cortés-Grimaldo, I. Skrindo, Piotr Kuna, Nicola Scichilone, Antonella Muraro, Kimihiro Okubo, Paulo Augusto Moreira Camargos, C. Cartier, Oliver Pfaar, K. Ohta, Barbara P. Yawn, Igor Kaidashev, Michel Thibaudon, X. Basagana, I. Kaidashev, Bilun Gemicioglu, S. Genova, Hae-Sim Park, J.J. Matta Campos, Simon Walker, Ulf Darsow, Fulvio Braido, J. Salimäki, T. Zuberbier, Raphaël Chiron, Mohammad Reza Masjedi, G.D. Marshall, Branislava Milenkovic, W. J. Fokkens, Eric D. Bateman, Robert M. Naclerio, Steve Montefort, M. de Fátima Emerson, T. Werfel, Cemal Cingi, A. Szylling, Martin Wagenmann, I. Baiardini, L. T. T. Le, N. Khaltaev, Ki-Suck Jung, Agnieszka Lipiec, Panayiotis K. Yiallouros, A Valero, R. Gerth van Wijk, L. Hernández, Marek L. Kowalski, C. Zubrinich, Sinthia Bosnic-Anticevich, Miguel A. Sierra, Erik Melén, T. Haahtela, Rute Almeida, Violeta Kvedariene, R. Pawankar, T.A. Popov, Flore Amat, Sanna Toppila-Salmi, M. Gotua, A. Sheikh, A. Bedbrook, Torsten Zuberbier, B. De Martino, Gérard Dray, Francesca Avolio, E. Mandajieva, B. Samolinski, Petr Panzner, P. Kuna, Philippe-Jean Bousquet, T. D. Nyembue, Luo Zhang, Leyla Namazova-Baranova, Ana Maria Carriazo, João Fonseca, E. Van Ganse, Roland Buhl, M. Bochenska Marciniak, Cristiana Stellato, J. da Silva, J. E. Gereda, Han-Jung Park, M.C. Costa-Dominguez, W. Carr, Dirceu Solé, S. Forti, Nanshan Zhong, Jordi Sunyer, Alain Didier, Y. Z. Chen, Thomas B. Casale, Jim Phillips, Isabelle Bosse, Manuel Teixeira Veríssimo, D. Y. Wang, U. Trama, Cristina Bárbara, David Somekh, T. Camuzat, R. N. Naclerio, Enrico Novellino, Leszek Klimek, M. Rodriguez Gonzalez, Holger J. Schünemann, Mario Barbagallo, D. Larenas-Linnemann, Mario Sánchez-Borges, Massimo Triggiani, Y. Okamoto, E. Mathieu-Dupas, N. Di Carluccio, S. Toppila-Salmi, Omer Kalayci, Rudolf Valenta, J. Coll, F. de Blay, Wienczyslawa Czarlewski, W. Pohl, Piotr Wroczyński, Kian Fan Chung, Nikolaos G. Papadopoulos, Pascal Demoly, Hubert Blain, M. Crescenzo, O. Kalayci, Leocadio Rodríguez-Mañas, G. Moda, L. Cox, Z. Gutter, A. Mair, Andrew Bush, Maria-Dolores Mogica-Martinez, Giorgio Walter Canonica, Antonio Valero, Daniel Laune, A. Zurkuhlen, Paul C. Potter, D. Wallace, Gabrielle L. Onorato, Mihaela Zidarn, E.P. Prokopakis, Anne Lise Courbis, Sergio Bonini, Ruta Dubakiene, A. Papi, Y. El-Gamal, Jacques Mercier, Wytske Fokkens, Rodolphe Bourret, S. Palkonen, A. Yorgancioglu, G. Vezzani, J. A. Rizzo, D. Plavec, D. Caillot, G. De Feo, E. Menditto, Caterina Bucca, A. C. Pozzi, Hironori Sagara, I. Grisle, I. Pin, Christopher E. Brightling, Ludger Klimek, F.F. Morato-Castro, Désirée Larenas-Linnemann, Alessandro Vatrella, A. A. Cruz, Guy Joos, E.D. Bateman, Erendira Rodriguez-Zagal, H. Douagui, T. To, Edgardo Jares, C. Bindslev-Jensen, G. Levato, J. O. B. Hourihane, R. Rajabian-Soderlund, C. Odzhakova, J. Bousquet, M. T. Ventura, Arzu Yorgancioglu, Osman M. Yusuf, H. J. Zar, Giovanni Rolla, Sebastian L. Johnston, M.S. Dykewicz, Esben Eller, A. Gamkrelidze, Filip Raciborski, Renzo Angles, Rafael Stelmach, M. Nogues, David Price, Mário Morais-Almeida, Tari Haahtela, Teresa To, D. Conforti, Stephen R. Durham, S. Gonzalez Diaz, V. Cardona, Werner Aberer, B. Milenkovic, Luigi Napoli, K. C. Bergmann, P W Hellings, M. Lessa, P. Panzner, Alfonso M. Cepeda Sarabia, M. Guidacci, A.L. Matos, Todor A. Popov, C. Suppli Ulrik, Diana Deleanu, N. de Paula Motta Rubini, Carsten Bindslev-Jensen, I. Majer, Ioana Agache, B. A. Barreto, R. Picard, Erkka Valovirta, A. Fink-Wagner, L. Colas, João O. Malva, Thomas Keil, M. T. Burguete Cabañas, Bolesław Samoliński, M.H. Garcia-Cruz, L.P. Boulet, K. Nekam, Edyta Krzych-Fałta, P. Devillier, J. Ferreira de Mello, Jussi Karjalainen, I. Bogus-Buczynska, Susan Waserman, Marcus Maurer, Tomas Chivato, Elena Bacci, M. Przemecka, Olga Lourenço, José Miguel Fuentes-Pérez, M. Zidarn, Talant Sooronbaev, J.M. Anto, W. Czarlewski, R. Murray, Luís Nogueira-Silva, G. Passalacqua, E. Chkhartishvili, Oscar Mayora, Victoria Cardona, M. Sondermann, Piotr Lacwik, S. Ouedraogo, I. Baroni, Artur Z. Białoszewski, G Scadding, J. Strozek, R. Emuzyte, Neven Miculinic, Ruby Pawankar, Ken Ohta, I. Agache, J.L. Gálvez-Romero, Nikos G. Papadopoulos, E. O. Meltzer, I. Annesi-Maesano, E. De Manuel Keenoy, Jorge A. Luna-Pech, Ana Margarida Pereira, Paul Potter, M. Ortega Cisneros, J. Li, K. F. Rabe, M. Rottem, Mikael Benson, Ali Fuat Kalyoncu, Dermot Ryan, Dieter Maier, C.Y. García-Cobas, S. Bialek, G. Du Toit, S. Shamai, S. Mavale-Manuel, Rojin Rajabian-Soderlund, Maddalena Illario, Philippe Devillier, F. Rodenas, Emmanuel P. Prokopakis, De Yun Wang, Niels H. Chavannes, E.H.D. Bel, Bianca Beghe, Sietze Reitsma, John Wright, O. Lourenço, L.T.T. Le, Josep M. Antó, T. Casale, Paul K. Keith, K. C. Lødrup Carlsen, P. Demoly, Mikael Kuitunen, Marc Humbert, A. M. Cepeda Sarabia, Ignacio J. Ansotegui, M.C. Rizzo, Davide Caimmi, Milan Sova, Nick A. Guldemond, P. Yakovliev, Judah A. Denburg, Jaime Correia de Sousa, Elisabete Melo-Gomes, Aziz Sheikh, I. Bosse, M. M. Ciaravolo, S. Di Capua Ercolano, Alpana Mair, P. Lieberman, Isabella Pali-Schöll, Leif Bjermer, G. De Vries, M. Roman Rodriguez, Johanna Salimäki, Carmen Panaitescu, F. Mihaltan, Giulia De Feo, F. E. R. Simons, A. Blua, B. Mahboub, D. Ryan, M. Bewick, Anabela Mota-Pinto, J.A. Fonseca, Neil Wilson, Marek Jutel, Dennis M. Williams, M. Akdis, Menachem Rottem, Marcello Persico, J. C. Ivancevich, Nelson Rosario, A. Farsi, Alvaro A. Cruz, Liguo Zhang, Anna Bedbrook, L. Bertorello, Magnus Wickman, Marilyn Urrutia-Pereira, O. Spranger, René Maximiliano Gómez, C. Bachert, Renaud Louis, Musa Khaitov, C. Stellato, Constantinos Pitsios, Roland Buonaiuto, A. Romano, Sîan A Williams, R. Puy, Daniela Rivero-Yeverino, Y. Mohammad, J. Farrell, Jan Brozek, Ricardo Pio Monti, E. Paulino, J. Correia de Sousa, Miguel Alejandro Medina-Ávalos, Jocelyne Just, Peter Valentin Tomazic, Jean-François Ferrero, Antoine Magnan, S. Waserman, J Rosado-Pinto, Maciek Kupczyk, C.S. Bosnic-Anticevich, T. Dedeu, Tommi Vasankari, R. Mösges, Robin O'Hehir, Ema Paulino, Peter Hellings, A. Neou, M. Wickman, D. Lauri, Jean Bousquet, A. Ciceran, Jacques Bouchard, Yehia El-Gamal, M.G. Dominguez-Silva, M.R. Alberti, Jean-Louis Pépin, Kimi Okubo, Juan Carlos Ivancevich, Patrik Eklund, Benoit Pugin, C. Dario, Mussa Khaitov, Luisa Brussino, A.G. Chuchalin, Elísio Costa, Susanna Palkonen, Lars Münter, Pedro Carreiro-Martins, R.E. Pulido Ross, Ettore Novellino, Kai-Håkon Carlsen, María Antonieta Guzmán, G.W. Canonica, Gabriel Onorato, Giuseppe De Carlo, R.E. Roller-Wirnsberger, Brian J. Lipworth, M. A. Guzman, J.N. Tebyriçá, Adnan Custovic, Yoshitaka Okamoto, Rimantas Stukas, P. Manning, J. Sastre-Dominguez, Caroline L.S. George, Robyn E O'Hehir, K. Maciej, Bassam Mahboub, J. F. Fontaine, Arũnas Valiulis, Xavier Rodó, D. Vicheva, G. Canfora, Vitalis Briedis, S. Rodrigues Valle, Mark S. Dykewicz, Joanne Rimmer, G. Castellano, B. Pigearias, A. L. Boner, Yunuen Rocío Huerta-Villalobos, Christine Rolland, H. Neffen, H. Arshad, Javier Gómez-Vera, P. Moura Santo, Frederic Viart, F. Blasi, J. Garcia-Aymerich, Lorenzo Cecchi, V. Niedeberger, Giorgio Ciprandi, F. Caballero-Fonseca, Jean-François Fontaine, J Mullol, Maurizio Romano, M. Viegi, Mario E. Zernotti, Arunas Valiulis, Anna Asarnoj, Antonio Nieto, J. Lavrut, D. Dokic, V. Kvedariene, Ewa Jassem, Cezmi A. Akdis, Ruth Murray, Claus Bachert, Peter Schmid-Grendelmeier, Emilie Burte, Joaquim Mullol, Guido Iaccarino, J. Kleine-Tebbe, P. V. Tomazic, E. Eller, Alessandro Fiocchi, H.J. Schunemann, M. Sorlini, C. Robalo-Cordeiro, Ana-Maria Todo-Bom, J. Brozek, Marco Nalin, Matteo Bonini, J. C. Sisul, S.E. Dahlen, F. Amat, Juan Carlos Sisul, Jawad Hajjam, Ana Todo-Bom, Enrica Menditto, Bousquet J., Hellings P.W., Agache I., Amat F., Annesi-Maesano I., Ansotegui I.J., Anto J.M., Bachert C., Bateman E.D., Bedbrook A., Bennoor K., Bewick M., Bindslev-Jensen C., Bosnic-Anticevich S., Bosse I., Brozek J., Brussino L., Canonica G.W., Cardona V., Casale T., Cepeda Sarabia A.M., Chavannes N.H., Cecchi L., Correia de Sousa J., Costa E., Cruz A.A., Czarlewski W., De Carlo G., De Feo G., Demoly P., Devillier P., Dykewicz M.S., El-Gamal Y., Eller E.E., Fonseca J.A., Fontaine J.-F., Fokkens W.J., Guzman M.-A., Haahtela T., Illario M., Ivancevich J.-C., Just J., Kaidashev I., Khaitov M., Kalayci O., Keil T., Klimek L., Kowalski M.L., Kuna P., Kvedariene V., Larenas-Linnemann D., Laune D., Le L.T.T., Carlsen K.L., Lourenco O., Mahboub B., Mair A., Menditto E., Milenkovic B., Morais-Almeida M., Mosges R., Mullol J., Murray R., Naclerio R., Namazova-Baranova L., Novellino E., O'Hehir R.E., Ohta K., Okamoto Y., Okubo K., Onorato G.L., Palkonen S., Panzner P., Papadopoulos N.G., Park H.-S., Paulino E., Pawankar R., Pfaar O., Plavec D., Popov T.A., Potter P., Prokopakis E.P., Rottem M., Ryan D., Salimaki J., Samolinski B., Sanchez-Borges M., Schunemann H.J., Sheikh A., Sisul J.-C., Rajabian-Soderlund R., Sooronbaev T., Stellato C., To T., Todo-Bom A.-M., Tomazic P.-V., Toppila-Salmi S., Valero A., Valiulis A., Valovirta E., Ventura M.-T., Wagenmann M., Wang D.Y., Wallace D., Waserman S., Wickman M., Yorgancioglu A., Zhang L., Zhong N., Zidarn M., Zuberbier T., Aberer W., Akdis C.A., Akdis M., Alberti M.R., Almeida R., Angles R., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Basagana X., Bedolla-Barajas M., Beghe B., Bel E.H., Bergmann K.C., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bouchard J., Boulet L.P., Bourret R., Braido F., Briedis V., Brightling C.E., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillot D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Castellano G., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Cortes-Grimaldo R.M., Corti F., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Dahlen S.E., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., Dedeu T., de Fatima Emerson M., De Vries G., De Martino B., de Paula Motta Rubini N., Deleanu D., Denburg J.A., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Eklund P., Emuzyte R., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Aymerich J., Garcia-Cobas C.Y., Garcia-Cruz M.H., Gemicioglu B., Genova S., George C., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Hajjam J., Hernandez L., Hourihane J.O., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Jutel M., Kalyoncu A.F., Karjalainen J., Kardas P., Keith P.K., Khaltaev N., Kleine-Tebbe J., Kuitunen M., Kull I., Kupczyk M., Krzych-Falta E., Lacwik P., Lauri D., Lavrut J., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Luna-Pech J.A., Maciej K., Magnan A., Maier D., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Mathieu-Dupas E., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Medina-Avalos M.A., Melen E., Melo-Gomes E., Meltzer E.O., Mercier J., Miculinic N., Mihaltan F., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Monti R., Mora Bogado D., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Nadif R., Nalin M., Napoli L., Neffen H., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Nyembue T.D., Odzhakova C., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Papi A., Passalacqua G., Pedersen S., Pepin J.L., Pereira A.M., Persico M., Phillips J., Picard R., Pigearias B., Pin I., Pitsios C., Pohl W., Portejoie F., Pozzi A.C., Price D., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Reitsma S., Ribeirinho I., Rimmer J., Rivero-Yeverino D., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rodriguez-Zagal E., Rolla G., Roller-Wirnsberger R.E., Romano M., Rosado-Pinto J., Rosario N., Sagara H., Sastre-Dominguez J., Scadding G.K., Scichilone N., Schmid-Grendelmeier P., Serpa F.S., Shamai S., Sierra M., Simons F.E.R., Siroux V., Skrindo I., Sole D., Somekh D., Sondermann M., Sova M., Sorensen M., Sorlini M., Spranger O., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., van Eerd M., van Ganse E., van Hague M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi M., Vicheva D., Vontetsianos T., Walker S., Werfel T., Westman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zernotti M.E., Zubrinich C., Zurkuhlen A., Bousquet, Jean, Hellings, Peter W., Agache, Ioana, Amat, Flore, Annesi-Maesano, Isabella, Ansotegui, Ignacio J., Anto, Josep M., Bachert, Clau, Bateman, Eric D., Bedbrook, Anna, Bennoor, Kazi, Bewick, Mickael, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Bosse, Isabelle, Brozek, Jan, Brussino, Luisa, Canonica, Giorgio W., Cardona, Victoria, Casale, Thoma, Cepeda Sarabia, Alfonso M., Chavannes, Niels H., Cecchi, Lorenzo, Correia de Sousa, Jaime, Costa, Elisio, Cruz, Alvaro A., Czarlewski, Wienczyslawa, De Carlo, Giuseppe, De Feo, Giulia, Demoly, Pascal, Devillier, Philippe, Dykewicz, Mark S., El-Gamal, Yehia, Eller, Esben E., Fonseca, Joao A., Fontaine, Jean-Françoi, Fokkens, Wytske J., Guzmán, Maria-Antonieta, Haahtela, Tari, Illario, Maddalena, Ivancevich, Juan-Carlo, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, Kalayci, Omer, Keil, Thoma, Klimek, Ludger, Kowalski, Marek L., Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Desiree, Laune, Daniel, Le, Lan T. T., Carlsen, Karin Lodrup, Lourenço, Olga, Mahboub, Bassam, Mair, Alpana, Menditto, Enrica, Milenkovic, Branislava, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Murray, Ruth, Naclerio, Robert, Namazova-Baranova, Leyla, Novellino, Ettore, O'Hehir, Robyn E., Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimi, Onorato, Gabrielle L., Palkonen, Susanna, Panzner, Petr, Papadopoulos, Nikos G., Park, Hae-Sim, Paulino, Ema, Pawankar, Ruby, Pfaar, Oliver, Plavec, Davor, Popov, Ted A., Potter, Paul, Prokopakis, Emmanuel P., Rottem, Menachem, Ryan, Dermot, Salimäki, Johanna, Samolinski, Boleslaw, Sanchez-Borges, Mario, Schunemann, Holger J., Sheikh, Aziz, Sisul, Juan-Carlo, Rajabian-Söderlund, Rojin, Sooronbaev, Talant, Stellato, Cristiana, To, Teresa, Todo-Bom, Ana-Maria, Tomazic, Peter-Valentin, Toppila-Salmi, Sanna, Valero, Antonio, Valiulis, Aruna, Valovirta, Erkka, Ventura, Maria-Teresa, Wagenmann, Martin, Wang, De Yun, Wallace, Dana, Waserman, Susan, Wickman, Magnu, Yorgancioglu, Arzu, Zhang, Luo, Zhong, Nanshan, Zidarn, Mihaela, Zuberbier, Torsten, Bousquet, J., Hellings, P. W., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Alberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Bachert, C., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Basagana, X., Bateman, E. D., Bedolla-Barajas, M., Bedbrook, A., Bewick, M., Beghé, B., Bel, E. H., Bergmann, K. C., Bennoor, K. S., Benson, M., Bertorello, L., Białoszewski, A. Z., Bieber, T., Bialek, S., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A. L., Bonini, M., Bonini, S., Bosnic-Anticevich, C. S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briedis, V., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabañas, M. T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillot, D., Caimmi, D., Calderon, M. A., Camargos, P. A. M., Camuzat, T., Canfora, G., Canonica, G. W., Cardona, V., Carlsen, K. H., Carreiro-Martins, P., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda Sarabia, A. M., Chavannes, N. H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciaravolo, M. M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A. C., Colas, L., Colgan, E., Coll, J., Conforti, D., Correia de Sousa, J., Cortés-Grimaldo, R. M., Corti, F., Costa, E., Costa-Dominguez, M. C., Courbis, A. L., Cox, L., Crescenzo, M., Cruz, A. A., Custovic, A., Czarlewski, W., Dahlen, S. E., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fátima Emerson, M., De Feo, G., De Vries, G., De Martino, B., de Paula Motta Rubini, N., Deleanu, D., Demoly, P., Denburg, J. A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M. G., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fokkens, W. J., Fonseca, J. A., Fontaine, J. F., Forti, S., Fuentes-Perez, J. M., Gálvez-Romero, J. L., Gamkrelidze, A., Garcia-Aymerich, J., García-Cobas, C. Y., Garcia-Cruz, M. H., Gemicioğlu, B., Genova, S., George, C., Gereda, J. E., Gerth van Wijk, R., Gomez, R. M., Gómez-Vera, J., González Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N. A., Gutter, Z., Guzmán, M. A., Haahtela, T., Hajjam, J., Hernández, L., Hourihane, J. O. 'B., Huerta-Villalobos, Y. R., Humbert, M., Iaccarino, G., Illario, M., Ivancevich, J. C., Jares, E. J., Jassem, E., Johnston, S. L., Joos, G., Jung, K. S., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Kardas, P., Keil, T., Keith, P. K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Klimek, L., Kowalski, M. L., Kuitunen, M., Kull, I., Kuna, P., Kupczyk, M., Kvedariene, V., Krzych-Fałta, E., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Le, L. T. T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lourenço, O., Luna-Pech, J. A., Maciej, K., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matta Campos, J. J., Matos, A. L., Maurer, M., Mavale-Manuel, S., Mayora, O., Medina-Avalos, M. A., Melén, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Momas, I., Montefort, S., Monti, R., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F. F., Mösges, R., Mota-Pinto, A., Moura Santo, P., Mullol, J., Münter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T. D., O'Hehir, R. E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G. L., Ortega Cisneros, M., Ouedraogo, S., Pali-Schöll, I., Palkonen, S., Panzner, P., Papadopoulos, N. G., Park, H. S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pépin, J. L., Pereira, A. M., Persico, M., Pfaar, O., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Potter, P., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Pulido Ross, R. E., Przemecka, M., Rabe, K. F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Mañas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R. E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimäki, J., Samolinski, B., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schunemann, H. J., Scichilone, N., Schmid-Grendelmeier, P., Serpa, F. S., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Solé, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyriçá, J. N., Thibaudon, M., To, T., Todo-Bom, A., Tomazic, P. V., Toppila-Salmi, S., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hague, M., Vandenplas, O., Ventura, M. T., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M. T., Viart, F., Viegi, M., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B. P., Yiallouros, P. K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zhang, L., Zhong, N., Zernotti, M. E., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Laboratory of clinical immunology, Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia [Bilbao], Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hacettepe University = Hacettepe Üniversitesi, Mechanobiology Institute [Singapore] (MBI), National University of Singapore (NUS), Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University [Hamilton, Ontario], Department of Dermatology [Graz, Austria], Medical University Graz, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Department Engineering Quimica (ICEMS), Ghent University Hospital, Istituto Nazionale di Fisica Nucleare, sezione di Bari (INFN, sezione di Bari), Istituto Nazionale di Fisica Nucleare (INFN), IMIM-Hospital del Mar, Generalitat de Catalunya, University of Cape Town, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Centre de gérontologie, Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, Woolcock Institute of Medical Research [Sydney], The University of Sydney, Université Laval [Québec] (ULaval), Departments of Clinical Epidemiology and Biostatistics and Medicine [Ontario], Service greffe de moelle osseuse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Royal Brompton Hospital, Région Languedoc-Roussillon-Midi-Pyrénées, Vall d'Hebron University Hospital [Barcelona], University of South Florida [Tampa] (USF), Università degli Studi di Firenze = University of Florence (UniFI), University of Michigan, Department of Atmospheric, Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Russian State Medical University, Universidade do Porto, Instituto de Biologia Molecular e Celular (IBMC), UCB Pharma, Colombes, Hôpital Gui de Chauliac [CHU Montpellier], CHU Strasbourg, European Federation of Allergy (EFA), Airways Diseases Patients' Associations, Università degli Studi di Salerno = University of Salerno (UNISA), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Linköping University (LIU), Department of Dermatology and Allergy Centre, Odense University Hospital, Vilnius University [Vilnius], Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, Institut d'Electronique du Solide et des Systèmes (InESS), Centre National de la Recherche Scientifique (CNRS), Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Center for Allergy and Immunology Research [Tbilisi], Department of Dermatology, Helsinki University Hospital-Skin and Allergy Hospital, Swedish Meteorological and Hydrological Institute (SMHI), CORYSS-TESS, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Biologie des organismes marins et écosystèmes (BOME), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), NRC Institute of immunology FMBA, Moscow Russian federation, Allergy and Asthma Center Westend, German Society for Otorhinolaryngology HNS, Rheinische Friedrich-Wilhelms-Universität Bonn, The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Medical University of Łódź (MUL), Hospital Medica Sur, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Applied Physical Chemistry Laboratory (APCLab), Institute of Geophysics and Planetary Physics [Los Angeles] (IGPP), University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), Équipe de Recherche en Textes, Informatique, Multilinguisme (ERTIM), Institut National des Langues et Civilisations Orientales (Inalco), Institute of Oceanology [China], University of Beira Interior [Portugal] (UBI), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Pulmonary and allergy unit, American University of Sharjah-Rashid Hospital-Dubai Health Authority (DHA), Astrophysique Interprétation Modélisation (AIM (UMR7158 / UMR_E_9005 / UM_112)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), 'Federico II' University of Naples Medical School, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Pneumology Department, Marius Nasta Institute of Pneumology, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Allergy and Clinical Immunology Department, Hospital CUF Descobertas, Universität zu Köln = University of Cologne, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Section of Otolaryngology-Head & Neck Surgery (OHNS), University of Chicago, Department of Pharmacy Naples, Université de Naples, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Dept. of Electronic Engineering, Chubu University, Department of Otorhinolaryngology, Chiba University Hospital, Department of Allergology and Clinical Immunology, Charles University [Prague] (CU)-Medical Faculty in Pilsen, Department of Earth and Planetary Sciences [Cambridge, USA] (EPS), Harvard University, Allergy and Respiratory Diseases, Università degli studi di Genova = University of Genoa (UniGe), Department of Pediatrics, Nippon Medical School, Centre Hospitalier Universitaire [Grenoble] (CHU), Department of Otorhinolaryngology, Head and Neck Surgery [Mannheim, Germany], University Hospital Mannheim, Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Children’s Hospital Srebrnjak [Zagreb, Croatia], Department of Physics [UMIST Manchester], University of Manchester Institute of Science and Technology (UMIST), Laboratori Nazionali del Sud (LNS), Getafe University Hospital, Madrid, Karl-Franzens-Universität Graz, Ecologie comportementale (EC), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes (UR)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Allergy Asthma and Immunology [Haifa, Israel], Ha'Emek Medical Center, Afula-Rappaport Faculty of Medicine, University of Edinburgh, Medical University of Warsaw - Poland, Department of Allergy and Clinical Immunology [Caracas, Venezuela], Centro Médico Docente La Trinidad, Department of Computer Science [Haifa], University of Haifa [Haifa], Allergy and Respiratory Research Group, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), National Centre of Cardiology and Internal Medicine, Ministry of Health Kyrgyz Republic, Réseau National de Surveillance Aérobiologique (RNSA), Berkeley Seismological Laboratory, Division of Clinical Immunology and Allergy, University of Naples Federico II = Università degli studi di Napoli Federico II, CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, Vilnius University Clinic of Children's Diseases, Suomen Terveystalo Allergy Clinic, Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre d'EPistémologie et d'ERgologie Comparatives (CEPERC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institute for Climate and Atmospheric Science [Leeds] (ICAS), School of Earth and Environment [Leeds] (SEE), University of Leeds-University of Leeds, Nova Southeastern University (NSU), Department of Otolaryngology, National University of Singapore (NUS)-Yong Loo Lin School of Medicine, Sachs' Children's Hospital, IAES, Department of Pulmonology, Manisa Celal Bayar University, Center for Evolutionary and Theoretical Immunology [Albuquerque, New Mexico] (CETI), The University of New Mexico [Albuquerque], National Key State Laboratory for ThermoStructural Composites (TSCM), Northwestern Polytechnical University [Xi'an] (NPU), Respiratory and Allergic Diseases, University Clinic of Respiratory and Allergic Diseases Golnik, University Hospital of Cologne [Cologne], Supported by the European Innovation Partnership on Active and Healthy Ageing and POLLAR (EIT Health, European Union)., European Project: 643803,H2020,H2020-HCO-2014,PROEIPAHA(2015), UCL - (MGD) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidemiology of Allergic and Respiratory Diseases Department [Paris] (EPAR), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Quiròn Bizkaia Erandio, Université Pierre et Marie Curie - Paris 6 (UPMC), University of Milan, University of Naples Federico II-CNR, Rome, Italy and Department of Medicine, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Università degli Studi di Salerno (UNISA), Institut de Physique du Globe de Paris (IPGP), Centre National de la Recherche Scientifique (CNRS)-Université de La Réunion (UR)-Université Paris Diderot - Paris 7 (UPD7)-IPG PARIS-Institut national des sciences de l'Univers (INSU - CNRS), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]-Epidemiology and Health Economics, Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Muséum national d'Histoire naturelle (MNHN), University of California-University of California, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospital CUF-Descobertas, Universität zu Köln, Medical Faculty in Pilsen-Charles University in Prague - the First Faculty of Medicine, Harvard University [Cambridge], University of Genoa (UNIGE), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), University of Graz, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université Claude Bernard Lyon 1 (UCBL), Centro Medico-Docente La Trinidad, Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Università degli studi di Napoli Federico II, Center for Evolutionary and theoretical Immunology, Biology, National Institute for Health Research, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Karl-Franzens-Universität [Graz, Autriche], Department of Dermatology, Allergology and Venereology, Clinicum, University of Helsinki, Children's Hospital, Faculty of Law, HUS Children and Adolescents, HUS Inflammation Center, University Hospitals Leuven [Leuven], Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, University of Zürich [Zürich] (UZH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of South Florida (USF), Università degli Studi di Firenze = University of Florence [Firenze], Laboratoire Magmas et Volcans (LMV), Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Universidade do Porto [Porto], Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin -Epidemiology and Health Economics, Université Pierre et Marie Curie - Paris 6 (UPMC)-Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre de Biologie pour la Gestion des Populations (UMR CBGP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de la Recherche Agronomique (INRA)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Université de Montpellier (UM)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Sondra, CentraleSupélec, Université Paris-Saclay (COmUE) (SONDRA), ONERA-CentraleSupélec-Université Paris Saclay (COmUE), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), RNSA, Centre d'EPistémologie et d'ERgologie Comparatives - UMR 7304 (CEPERC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), National Institute for Nuclear Physics (INFN), Université Laval, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Università degli Studi di Firenze [Firenze], University of Salerno (UNISA), Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Sondra, CentraleSupélec, Université Paris-Saclay (SONDRA), ONERA-CentraleSupélec-Université Paris-Saclay, Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), École normale supérieure - Paris (ENS Paris)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes 1 (UR1), Universidade do Minho, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, uBibliorum, and Internal Medicine
Subjects: Allergy, Medicina Básica [Ciências Médicas], asthma -- guideline, Allergic asthma, DECISION-MAKING, Allergic Rhinitis and Its Impact on Asthma, GUIDELINES, Medical and Health Sciences, Medical Records, 0302 clinical medicine, Health care, Immunology and Allergy, 030212 general & internal medicine, asthma, Change management, rhinitis, Immunology, MASK-RHINITIS, ComputingMilieux_MISCELLANEOUS, Rinitis, mobilne aplikacije, upravljanje sprememb, Medical record, GLOBAL STRATEGY, WORK PRODUCTIVITY, Telemedicine, mobile applications, 3. Good health, Asma alérgica, rhiniti, 1107 Immunology, Ciências Médicas::Medicina Básica, klinične poti, allergic -- guideline, Life Sciences & Biomedicine, Human, PATIENT PARTICIPATION, Allergic Rhinitis, medicine.medical_specialty, animal structures, multimorbidity, EUROPEAN INNOVATION PARTNERSHIP, Change Management, [object Object], Settore MED/10 - Malattie Dell'Apparato Respiratorio, Asthma/diagnosis, CHRONIC DISEASES, MACVIA-ARIA, 03 medical and health sciences, medicine, multimorbidnost, QUALITY, Humans, critical pathways, astma -- smernica, Patient participation, Asma, udc:616.2, Asthma, Science & Technology, ARIA, business.industry, Multimorbidity, Rhinitis, Allergic, Settore MED/09 - MEDICINA INTERNA, change management, Mobile Airways Sentinel Network (MASK) Study Group, Guideline, ta3121, medicine.disease, Rinite alérgica, Rhinitis, Allergic/diagnosis, Integrated care, alergijski rinitis -- smernica, Allergic Rhinitis and Its Impact on Asthma, asthma, Change management, rhinitis, Immunology and Allergy, Immunology, 030228 respiratory system, Family medicine, 3121 General medicine, internal medicine and other clinical medicine, Medical Record, Clinical Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Impact on Asthma
Abstract: Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional., EAACI -European Academy of Allergy and Clinical Immunology(undefined), info:eu-repo/semantics/acceptedVersion
Published: 2018

40. Das Mikrobiom der oberen Atemwege im Hinblick auf die chronische Rhinosinusitis

Author: T. Chalermwatanachai, L.C. Velásquez, and C. Bachert
Subjects: Immunology and Allergy
Published: 2015

41. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report

Author: Cingi, C. Gevaert, P. Mösges, R. Rondon, C. Hox, V. Rudenko, M. Muluk, N.B. Scadding, G. Manole, F. Hupin, C. Fokkens, W.J. Akdis, C. Bachert, C. Demoly, P. Mullol, J. Muraro, A. Papadopoulos, N. Pawankar, R. Rombaux, P. Toskala, E. Kalogjera, L. Prokopakis, E. Hellings, P.W. Bousquet, J.
Abstract: This report has been prepared by the European Academy of Allergy and Clinical Immunology Task Force on Allergic Rhinitis (AR) comorbidities. The aim of this multidisciplinary European consensus document is to highlight the role of multimorbidities in the definition, classification, mechanisms, recommendations for diagnosis and treatment of AR, and to define the needs in this neglected area by a literature review. AR is a systemic allergic disease and is generally associated with numerous multi-morbid disorders, including asthma, eczema, food allergies, eosinophilic oesophagitis (EoE), conjunctivitis, chronic middle ear effusions, rhinosinusitis, adenoid hypertrophy, olfaction disorders, obstructive sleep apnea, disordered sleep and consequent behavioural and educational effects. This report provides up-to-date usable information to: (1) improve the knowledge and skills of allergists, so as to ultimately improve the overall quality of patient care; (2) to increase interest in this area; and (3) to present a unique contribution to the field of upper inflammatory disease. © 2017 The Author(s).
Published: 2017

42. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology

Author: Hellings, P.W. Klimek, L. Cingi, C. Agache, I. Akdis, C. Bachert, C. Bousquet, J. Demoly, P. Gevaert, P. Hox, V. Hupin, C. Kalogjera, L. Manole, F. Mösges, R. Mullol, J. Muluk, N.B. Muraro, A. Papadopoulos, N. Pawankar, R. Rondon, C. Rundenko, M. Seys, S.F. Toskala, E. Van Gerven, L. Zhang, L. Zhang, N. Fokkens, W.J.
Abstract: This EAACI position paper aims at providing a state-of-the-art overview on nonallergic rhinitis (NAR). A significant number of patients suffering from persistent rhinitis are defined as nonallergic noninfectious rhinitis (NANIR) patients, often denominated in short as having NAR. NAR is defined as a symptomatic inflammation of the nasal mucosa with the presence of a minimum of two nasal symptoms such as nasal obstruction, rhinorrhea, sneezing, and/or itchy nose, without clinical evidence of endonasal infection and without systemic signs of sensitization to inhalant allergens. Symptoms of NAR may have a wide range of severity and be either continuously present and/or induced by exposure to unspecific triggers, also called nasal hyperresponsiveness (NHR). NHR represents a clinical feature of both AR and NAR patients. NAR involves different subgroups: drug-induced rhinitis, (nonallergic) occupational rhinitis, hormonal rhinitis (including pregnancy rhinitis), gustatory rhinitis, senile rhinitis, and idiopathic rhinitis (IR). NAR should be distinguished from those rhinitis patients with an allergic reaction confined to the nasal mucosa, also called “entopy” or local allergic rhinitis (LAR). We here provide an overview of the current consensus on phenotypes of NAR, recommendations for diagnosis, a treatment algorithm, and defining the unmet needs in this neglected area of research. © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Published: 2017

43. ARIA-Versorgungspfade für die Allergenimmuntherapie 2019

Author: C. Bachert
Subjects: Immunology and Allergy
Published: 2019

44. Editorial

Author: C. Bachert
Subjects: Immunology and Allergy
Published: 2018

45. Überarbeitete S2k-Leitlinie zur (allergen-) spezifischen Immuntherapie

Author: C. Bachert
Subjects: Immunology and Allergy
Published: 2015

46. The Pathogenesis of CRS: An Update

Author: C. Bachert, Koen Van Crombruggen, Nada Al Bahrani, Surayie Al Dousary, Zhang Nan, Claudina Perez-Novo, and Olga Krysko
Subjects: education.field_of_study, biology, business.industry, Population, Disease, medicine.disease, Acquired immune system, Immunoglobulin E, Otorhinolaryngology, Fibrosis, Immunology, medicine, biology.protein, Immunology and Allergy, Surgery, Nasal polyps, Neurology (clinical), education, business, Interleukin 5, Asthma
Abstract: Chronic rhinosinusitis with or without polyps affects more than 10 % of the population. In the last decennium, great progress was made in the elucidation of relevant pathomechanisms of innate and adaptive immunity and in the recognition of potential environmental and intramucosal triggers. Inflammatory pathways and triggers need to be integrated into a modern concept of disease differentiation beyond the nasal endoscope; in short, remodeling and inflammatory processes can be described, involving fibrosis versus edema, which are related to the clinical phenotype; the signatures of a number of T helper cells decide on the subsequent granulocytic tissue reactions beyond the level of neutrophils versus eosinophils. Based on those pathways, biomarkers allow the prediction of the likelihood of co-morbid asthma and individual selection of appropriate treatments, from glucocorticosteroids and immune-modulatory antibiotics to innovative approaches such as humanized monoclonal antibodies against IgE and interleukin-5. These approaches currently serve as proof-of-concept tools, and will expand our armamentarium tomorrow.
Published: 2012

47. Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis

Author: R. Jund, M. Mondigler, H. Steindl, H. Stammer, P. Stierna, C. Bachert, and null ARhiSi II study group
Subjects: Adult, Male, Drug, Pathology, medicine.medical_specialty, Dry Extract BNO 1016, media_common.quotation_subject, Placebo, law.invention, Young Adult, Double-Blind Method, Randomized controlled trial, law, Paranasal Sinuses, Humans, Medicine, In patient, Gentiana, Prospective Studies, Clinical efficacy, Sinusitis, Rumex, Aged, Rhinitis, Ultrasonography, media_common, Traditional medicine, Plant Extracts, business.industry, Verbena, General Medicine, Middle Aged, Treatment Outcome, Primula, Sambucus, Tolerability, Otorhinolaryngology, Acute Disease, Female, Phytotherapy, business
Abstract: Objective: A herbal drug combination (Dry Extract BNO 1016) has been assessed for efficacy and tolerability in patients with acute viral rhinosinusitis. Methodology: In this randomised, controlled trial patients with symptom duration of up to 3 days, mild to moderate facial pain and a Major Symptom Score (MSS) between 8 and 12 were treated for 15 days with BNO 1016 or placebo (coated tablets administered orally). Primary efficacy endpoint was mean MSS at end of treatment. Secondary outcome measures included treatment response and changes in paranasal sinuses assessed by ultrasonography. Results: Treatment resulted in clinically relevant, significant differences in mean MSS for BNO 1016 versus placebo. BNO 1016 provided symptom relief two days earlier than placebo. The number needed to treat for healing is 8. BNO 1016 was superior regarding responder rates at Day 10 and Day 14 and percentage of patients without signs of acute viral rhinosinusitis assessed by ultrasonography at end of treatment. BNO 1016 was well tolerated; no serious adverse events were reported. Conclusion: The herbal dry extract BNO 1016 is efficacious and well tolerated in patients with acute viral rhinosinusitis. Trial registration: ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT01146860; EudraCT: 2009-016682-28).
Published: 2012

48. Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA

Author: J S, Makowska, P, Burney, D, Jarvis, T, Keil, P, Tomassen, J, Bislimovska, G, Brozek, C, Bachert, J, Baelum, C, Bindslev-Jensen, J, Bousquet, P J, Bousquet, C, Kai-Håkon, S E, Dahlen, B, Dahlen, W J, Fokkens, B, Forsberg, M, Gjomarkaj, P, Howarth, E, Salagean, C, Janson, L, Kasper, U, Kraemer, C, Louiro, B, Lundback, J, Minov, E, Nizankowska-Mogilnicka, N, Papadopoulos, A G, Sakellariou, A, Todo-Bom, E, Toskala, J E, Zejda, T, Zuberbier, and M L, Kowalski
Subjects: Adult, Male, Adolescent, Anti-Inflammatory Agents, Non-Steroidal, Comorbidity, Middle Aged, Drug Hypersensitivity, Europe, Young Adult, Cross-Sectional Studies, Risk Factors, Population Surveillance, Odds Ratio, Prevalence, Respiratory Hypersensitivity, Humans, Female, Aged
Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most prevalent drugs inducing hypersensitivity reactions. The aim of this analysis was to estimate the prevalence of NSAID-induced respiratory symptoms in population across Europe and to assess its association with upper and lower respiratory tract disorders.The GAThe mean prevalence of NSAID-induced dyspnea was 1.9% and was highest in the three Polish centers [Katowice (4.9%), Krakow (4.8%), and Lodz (4.4%)] and lowest in Skopje, (0.9%), Amsterdam (1.1%), and Umea (1.2%). In multivariate analysis, the prevalence of respiratory reactions to NSAIDs was higher in participants with chronic rhinosinusitis symptoms (Odds Ratio 2.12; 95%CI 1.78-2.74), asthma symptoms in last 12 months (2.7; 2.18-3.35), hospitalization due to asthma (1.53; 1.22-1.99), and adults vs children (1.53; 1.24-1.89), but was not associated with allergic rhinitis.Our study documented significant variation between European countries in the prevalence of NSAID-induced respiratory hypersensitivity reactions, and association with chronic airway diseases, but also with environmental factors.
Published: 2016

49. MOESM1 of Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Author: J. Bousquet, J. Farrell, G. Crooks, P. Hellings, E. Bel, M. Bewick, N. Chavannes, J. Sousa, A. Cruz, T. Haahtela, G. Joos, N. Khaltaev, J. Malva, A. Muraro, M. Nogues, S. Palkonen, S. Pedersen, C. Robalo-Cordeiro, B. Samolinski, T. Strandberg, A. Valiulis, A. Yorgancioglu, T. Zuberbier, A. Bedbrook, W. Aberer, M. Adachi, A. Agusti, C. Akdis, M. Akdis, J. Ankri, A. Alonso, I. Annesi-Maesano, I. Ansotegui, J. Anto, S. Arnavielhe, H. Arshad, C. Bai, I. Baiardini, C. Bachert, A. Baigenzhin, C. Barbara, E. Bateman, B. Beghé, A. Kheder, K. Bennoor, M. Benson, K. Bergmann, T. Bieber, C. Bindslev-Jensen, L. Bjermer, H. Blain, F. Blasi, A. Boner, M. Bonini, S. Bonini, S. Bosnic-Anticevitch, L. Boulet, R. Bourret, P. Bousquet, F. Braido, A. Briggs, C. Brightling, J. Brozek, R. Buhl, P. Burney, A. Bush, F. Caballero-Fonseca, D. Caimmi, M. Calderon, P. Calverley, P. Camargos, G. Canonica, T. Camuzat, K. Carlsen, W. Carr, A. Carriazo, T. Casale, A. Cepeda Sarabia, L. Chatzi, Y. Chen, R. Chiron, E. Chkhartishvili, A. Chuchalin, K. Chung, G. Ciprandi, I. Cirule, L. Cox, D. Costa, A. Custovic, R. Dahl, S. Dahlen, U. Darsow, G. Carlo, F. Blay, T. Dedeu, D. Deleanu, E. Manuel Keenoy, P. Demoly, J. Denburg, P. Devillier, A. Didier, A. Dinh-Xuan, R. Djukanovic, D. Dokic, H. Douagui, G. Dray, R. Dubakiene, S. Durham, M. Dykewicz, Y. El-Gamal, R. Emuzyte, L. Fabbri, M. Fletcher, A. Fiocchi, A. Fink Wagner, J. Fonseca, W. Fokkens, F. Forastiere, P. Frith, M. Gaga, A. Gamkrelidze, J. Garces, J. Garcia-Aymerich, B. Gemicioğlu, J. Gereda, S. González Diaz, M. Gotua, I. Grisle, L. Grouse, Z. Gutter, M. Guzmán, L. Heaney, B. Hellquist-Dahl, D. Henderson, A. Hendry, J. Heinrich, D. Heve, F. Horak, J. Hourihane, P. Howarth, M. Humbert, M. Hyland, M. Illario, J. Ivancevich, J. Jardim, E. Jares, C. Jeandel, C. Jenkins, S. Johnston, O. Jonquet, K. Julge, K. Jung, J. Just, I. Kaidashev, M. Kaitov, O. Kalayci, A. Kalyoncu, T. Keil, P. Keith, L. Klimek, B. Koffi N’Goran, V. Kolek, G. Koppelman, M. Kowalski, I. Kull, P. Kuna, V. Kvedariene, B. Lambrecht, S. Lau, D. Larenas-Linnemann, D. Laune, L. Le, P. Lieberman, B. Lipworth, J. Li, K. Lodrup Carlsen, R. Louis, W. MacNee, Y. Magard, A. Magnan, B. Mahboub, A. Mair, I. Majer, M. Makela, P. Manning, S. Mara, G. Marshall, M. Masjedi, P. Matignon, M. Maurer, S. Mavale-Manuel, E. Melén, E. Melo-Gomes, E. Meltzer, A. Menzies-Gow, H. Merk, J. Michel, N. Miculinic, F. Mihaltan, B. Milenkovic, G. Mohammad, M. Molimard, I. Momas, A. Montilla-Santana, M. Morais-Almeida, M. Morgan, R. Mösges, J. Mullol, S. Nafti, L. Namazova-Baranova, R. Naclerio, A. Neou, H. Neffen, K. Nekam, B. Niggemann, G. Ninot, T. Nyembue, R. O’Hehir, K. Ohta, Y. Okamoto, K. Okubo, S. Ouedraogo, P. Paggiaro, I. Pali-Schöll, P. Panzner, N. Papadopoulos, A. Papi, H. Park, G. Passalacqua, I. Pavord, R. Pawankar, R. Pengelly, O. Pfaar, R. Picard, B. Pigearias, I. Pin, D. Plavec, D. Poethig, W. Pohl, T. Popov, F. Portejoie, P. Potter, D. Postma, D. Price, K. Rabe, F. Raciborski, F. Radier Pontal, S. Repka-Ramirez, S. Reitamo, S. Rennard, F. Rodenas, J. Roberts, J. Roca, L. Rodriguez Mañas, C. Rolland, M. Roman Rodriguez, A. Romano, J. Rosado-Pinto, N. Rosario, L. Rosenwasser, M. Rottem, D. Ryan, M. Sanchez-Borges, G. Scadding, H. Schunemann, E. Serrano, P. Schmid-Grendelmeier, H. Schulz, A. Sheikh, M. Shields, N. Siafakas, Y. Sibille, T. Similowski, F. Simons, J. Sisul, I. Skrindo, H. Smit, D. Solé, T. Sooronbaev, O. Spranger, R. Stelmach, P. Sterk, J. Sunyer, C. Thijs, T. To, A. Todo-Bom, M. Triggiani, R. Valenta, A. Valero, E. Valia, E. Valovirta, E. Ganse, M. Hage, O. Vandenplas, T. Vasankari, B. Vellas, J. Vestbo, G. Vezzani, P. Vichyanond, G. Viegi, C. Vogelmeier, T. Vontetsianos, M. Wagenmann, B. Wallaert, S. Walker, D. Wang, U. Wahn, M. Wickman, D. Williams, S. Williams, J. Wright, B. Yawn, P. Yiallouros, O. Yusuf, A. Zaidi, H. Zar, M. Zernotti, L. Zhang, N. Zhong, M. Zidarn, and J. Mercier
Abstract: Additional file 1. IPCRG scaling up activities.
Published: 2016
Full Text: View/download PDF

50. Prevalence of chronic rhinosinusitis in Sao Paulo

Author: R.R. Pilan, F.R. Pinna, T.F. Bezerra, R.L. Mori, F.G. Padua, R.F. Bento, C. Perez-Novo, C. Bachert, and R.L. Voegels
Subjects: Otorhinolaryngology, General Medicine
Published: 2012

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

1,008 results on '"C, Bachert"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources